



Cite this: *Chem. Soc. Rev.*, 2024, 53, 3253

Targeted protein degradation directly engaging lysosomes or proteasomes†

Jiseong Kim, ^{‡,ab} Insuk Byun, ^{‡,ab} Do Young Kim, ^{‡,c} Hyunhi Joh, ^c
 Hak Joong Kim ^{*c} and Min Jae Lee ^{*abd}

Targeted protein degradation (TPD) has been established as a viable alternative to attenuate the function of a specific protein of interest in both biological and clinical contexts. The unique TPD mode-of-action has allowed previously undruggable proteins to become feasible targets, expanding the landscape of “druggable” properties and “privileged” target proteins. As TPD continues to evolve, a range of innovative strategies, which do not depend on recruiting E3 ubiquitin ligases as in proteolysis-targeting chimeras (PROTACs), have emerged. Here, we present an overview of direct lysosome- and proteasome-engaging modalities and discuss their perspectives, advantages, and limitations. We outline the chemical composition, biochemical activity, and pharmaceutical characteristics of each degrader. These alternative TPD approaches not only complement the first generation of PROTACs for intracellular protein degradation but also offer unique strategies for targeting pathologic proteins located on the cell membrane and in the extracellular space.

Received 22nd November 2023

DOI: 10.1039/d3cs00344b

rsc.li/chem-soc-rev

Key learning points

- (1) A comprehensive overview of recent approaches in TPD, emphasizing ubiquitin-independent modalities from chemical and biological perspectives.
- (2) Chemical induction of autophagy-mediated degradation for elimination of intracellular proteins and organelles with pathological relevance.
- (3) Exploitation of lysosome-trafficking receptors for TPD of extracellular and membrane-associated proteins *via* the endosome–lysosome pathway.
- (4) Direct recruiting of the 26S proteasome to soluble proteins, a departure from the PROTAC technology based on target ubiquitination.
- (5) Comparative analysis on the advantages and limitations of ubiquitin-independent TPD technologies with a discussion on their therapeutic potentials.

1. Introduction: targeted protein degradation

Targeted protein degradation (TPD) has emerged as a compelling pharmacological modality for selective removal of disease-associated proteins.¹ In contrast to conventional small-molecule inhibitors or agonists/antagonists that typically require a high binding affinity with specific proteins, TPD can operate through comparably modest interactions between the targets (primarily

proteins but cellular organelles as well) and binding molecules (encompassing chemical compounds and biologics).^{2,3} The first-generation protein degraders, such as PROTeolysis-TArgeting Chimeras (PROTACs), are mainly synthetic heterobifunctional compounds that bind to a target protein on one end and recruit an E3 ubiquitin (Ub) ligase (or ligase complex) on the other end, connected by a diverse variety of linkers.^{4–7} The induced proximity between the hijacked E3 Ub ligase and “neo-substrate” in the cell leads to the forced polyubiquitination of the latter, resulting in its proteolysis by 26S proteasomes.⁸ Molecular glue degraders (MGDs) share a similar mode of action with PROTACs, chemically inducing a stable ternary complex with an E3 ligase and a target protein, have an analogous mode of action towards PROTACs.^{9–11} However, unlike PROTACs, MGDs lack the linker element and the capability to establish an intimate contact interface between two proteins. With their smaller size, MGDs can offer pharmacological advantages over PROTACs, albeit posing greater challenges for their rational chemical design.

As a therapeutic strategy, specific removal of disease-associated proteins offers several advantages compared to

^a Department of Biochemistry & Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Korea. E-mail: minjlee@snu.ac.kr

^b Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Korea

^c Department of Chemistry, College of Science, Korea University, Seoul 02841, Korea. E-mail: hakkim@korea.ac.kr

^d Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cs00344b>

‡ These authors contributed equally to this work.



conventional occupancy-driven drugs, which require stoichiometric target engagement.^{12,13} First, owing to their catalytic mode of action, PROTAC- and MGD-based drugs can exhibit

high potency even at low cellular concentrations. Protein degraders can also overcome the drug resistance originating from somatic mutations or structural/functional changes in



Jiseong Kim

Jiseong Kim graduated from Handong Global University (Korea) and received a BS in 2021. She then joined the group of Professor Min Jae Lee at Seoul National University College of Medicine and is currently in the PhD course. Her research interest is developing a new platform for targeted protein degradation that induces selective degradation of pathologic proteins.



Insuk Byun

Insuk Byun received his BS (2022) from Konkuk University, Seoul, Korea. He is currently pursuing his PhD degree under the supervision of Dr Min Jae Lee at Seoul National University College of Medicine. His research interests are developing anticancer drugs focusing on the ubiquitin-proteasome system and intracellular proteasome regulation.




Do Young Kim

Do Young Kim received his BS degree from Korea University in 2019 and completed his doctoral studies at the same university under the supervision of Dr Hak Joong Kim in 2024. His research interests have included repurposing antibacterial and anticancer drugs via developing an original drug delivery strategy. Currently, he is involved in the discovery of potent agents capable of inducing targeted degradation of secreted proteins relevant to cancer metastasis.



Hyunhi Joh

Hyunhi Joh graduated from the Department of Chemistry, Korea University and received a BS degree in 2023. She is currently studying under the supervision of Dr Hak Joong Kim at Korea University to pursue her master's degree. Her research interests include the discovery of novel targeted protein degradation agents and establishing a new screening platform based on the DNA-encoded library.



Hak Joong Kim

Hak Joong Kim is a professor in the Department of Chemistry at Korea University. He received his PhD degree under the guidance of Dr Hung-Wen Liu at the University of Texas at Austin and then joined Dr Peter G. Schultz at The Scripps Research Institute for postdoctoral research. His research interests include chemical biology and medicinal chemistry associated with infectious diseases and cancer, among which he currently focuses on the development of new

platforms for targeted protein degradation.



Min Jae Lee

Min Jae Lee is a Professor of Biochemistry at Seoul National University College of Medicine in Korea. He received his BS in chemistry from SNU and his PhD in pharmaceutical sciences from University of Pittsburgh School of Pharmacy. His research interests are intracellular protein degradation through the ubiquitin-proteasome system and autophagy, its pathophysiological implications, and the development of pharmacological methods. He has authored

>70 research papers with >5000 citations and was the recipient of the Research Excellent Prizes of the Korean Chemical Society (in 2016) and the Korean Society of Biochemistry and Molecular Biology (in 2019).



target proteins due to post-translational modifications (PTMs).¹⁴ PROTACs have enabled the targeting of scaffolding proteins and transcription factors that are therapeutically significant but usually lack well-defined binding pockets for conventional drugs, thereby expanding the range of druggable proteomes. Various PROTAC-based degraders have been developed, and their unique therapeutic potential has been demonstrated, with approximately 25 PROTAC drugs being under clinical trials and many more in the development pipeline.^{15–18}

PROTACs, MGD, and many other early TPD approaches function by exploiting the Ub-proteasome system (UPS), the predominant proteolytic route within the cytoplasm and nucleus of eukaryotes.¹⁹ The UPS also plays a pivotal role in maintaining the quality control of cellular proteins. For instance, misfolded proteins, generated *via* genetic mutations, transcriptional/translational errors, or PTM-mediated structural changes, undergo rapid polyubiquitination and proteasomal degradation (mostly < 10 min of an average half-life).^{20–22} The E3 Ub ligases play a critical role in determining substrate specificity by mediating a proximal interaction between the Ub-charged E2 Ub-conjugating enzymes and to-be-degraded substrates. The human genome encodes > 600 E3 Ub ligases,²³ but only a few have been employed for PROTACs; two E3s, CRBN and VHL, are responsible for ~94% of all PROTACs (Please note that a detailed discussion of E3s in TPD is outside the scope of this review. Readers interested on this topic are encouraged to consult recent excellent reviews^{24,25}).

Proteasomes are highly abundant (> 200 nM) and stable (half-life > 12 days) enzyme complexes present in most cell types,^{26–29} which makes them appropriate proteases for TPD. The 26S holoenzyme consists of two distinct and dissociable components—the 28-subunit catalytic complex (CP) and the 19-subunit regulatory complex (RP).³⁰ While the cylindrical CP retains active proteolytic sites in its interior, the RP interacts with the polyubiquitin (polyUb) chains of target substrates through multiple Ub receptors, including PSMD2/Rpn1, PSMD4/Rpn10, and ADRM1/Rpn13.³¹ Upon binding, the RP triggers substrate unfolding, opens the “gate” at the substrate translocation channel, and translocates the substrates into the CP for proteolysis.³² The catalytic PSMB5/β5, PSMB6/β1, and PSMB7/β2 subunits in the CP are threonine proteases; the hydroxyl groups on their N-terminal threonine residues initiate multiple, simultaneous nucleophilic attacks on peptide bonds, leading to proteolysis in a processive manner.³³

Proteasomes heterogeneously exist as a mixture of 20S (free CP as a stand-alone protease), 26S (singly-capped RP-CP), and 30S (doubly-capped RP₂-CP) subfamilies within a cell. It is notable that free 20S proteasomes, which cannot recognise polyUb chains, account for more than half of the total proteasome.^{34,35} The equilibrium between Ub-dependent proteasome holoenzymes (26S and 30S) and Ub-independent 20S proteasomes appears to be dynamically adjusted in response to environmental changes. Although the detailed mechanism remains to be identified, the abundance of 26S/30S proteasomes available in target cells is expected to influence the overall degradation efficiency of various PROTACs, which can

also be limited by the expression levels of hijacked E3 Ub ligases. When E3s are ubiquitously expressed, a TPD drug may exhibit “on-target, off-tumour” toxicity in healthy tissues.^{36,37} Overall, the mechanistic complexities involved in the UPS and the constant fluctuation of its proteolytic flux in diverse biological contexts imply that substrate polyubiquitination alone may not always be sufficient to trigger substrate degradation.³⁸ The development of PROTACs and MGDs capable of forming ternary complexes with acceptable druggability and pharmacological profiles continues to heavily rely on empirical trial-and-error methods both in the chemical (synthesis) and biological (assay) process.

While these potential limitations do not preclude the viability of PROTACs and other TPD modalities exploiting the UPS, it is noteworthy that a number of alternative strategies have been explored to circumvent these issues. Within a cellular environment, the UPS is complemented by another central degradation system—the autophagy-lysosome system (hereafter referred to as autophagy).³⁹ In contrast to the UPS, which operates continuously under physiological conditions, autophagy is primarily an inducible system that is activated only when cells are under relatively severe cellular stress, such as nutrient starvation, oxidative stress, and pathogen infection, thus providing metabolic intermediates and energy to cells and maintaining organelle homeostasis.^{40–42} Combined with lysosomes harbouring > 60 hydrolytic enzymes, autophagy can also degrade non-proteinaceous entities, such as nucleic acids, intracellular pathogens, mitochondria, endoplasmic reticulum (ER), and lipid droplets.^{43,44} Consequently, integrating autophagic degradation with the concept of TPD has considerably broadened the range of druggable targets.

In autophagy, microtubule-associated protein 1 light chain 3 (LC3) plays a critical role in the regulation of autophagosome biogenesis, cargo recruitment, and lysosomal fusion.⁴⁵ The biochemical cascade that involves the attachment of a phosphatidylethanolamine moiety to the C-terminal glycine of the cleaved LC3 (LC3-I) in autophagy resembles the E1-, E2-, and E3-mediated multistep Ub-conjugating system in the UPS.^{46,47} In contrast to the UPS that features hundreds of E3 Ub ligases, autophagy depends on only a handful of receptors connecting diverse cargoes to lipidated LC3 (LC3-II) on the phagophore membrane.^{46–48} Selective autophagy is known to be mediated by specific cargo receptors, such as SQSTM1/p62, NBR1, IPTN, NDP52, and TAX1BP1, all of which commonly feature an LC3-interacting region, a Ub-binding domain, and an oligomerisation domain. In non-selective, bulk autophagy, liquid-liquid phase separation, instead of specific cargo recognition, at the phagophore assembly site appears to be critical for importing substrates to the autophagosome.

It has been proposed that TPD modalities that do not require the complex and energy-intensive ubiquitination process as in PROTACs could offer distinct advantages from both technical and therapeutic standpoints. Recently, innovative TPD tools, including AuTophagy-TEthering Compounds (ATTEC),⁴⁹ LYSosome-TArgeting Chimeras (LYTAC),⁵⁰ AUTOPhagy-TArgeting Chimera (AUTOTAC),⁵¹ CytoKine receptor-TArgeting Chimera (KineTAC),⁵²






Fig. 1 The illustration of Ub-independent TPD strategies. Arginine–glycine–aspartic acid (RGD); asialoglycoprotein receptor (ASGPR); autophagy-targeting ligand (ATL); autophagy-tethering compound (ATTEC); autophagy-targeting chimera (AUTOTAC); cation-independent mannose-6-phosphate receptor (CI-M6PR); chemical inducers of degradation (CIDE); cytokine receptor-targeting chimeras (KineTAC); C-X-C motif chemokine ligand 12 (CXCL12); C-X-C chemokine receptor type 7 (CXCR7); dendronized DNA chimera (DENTAC); integrin-facilitated lysosomal degradation (IFLD); lysosome-targeting chimera (LYTAC); mannose-6-phosphate (M6P); molecular degraders of extracellular proteins through the ASGPR (MoDE-A); a protein-of-interest (POI); proteolysis-targeting chimera (PROTAC); scavenger receptor (SR); target-binding ligand (TBL); triantennary *N*-acetylgalactosamine (tri-GalNAc); ubiquitin-independent degrader (UID).

Integrin-Facilitated Lysosomal Degradation (IFLD),⁵³ and Dendronized DNA Chimera (DENTAC),⁵⁴ have been developed to hijack endogenous lysosomes through lysosomal trafficking receptors, LC3-II on the growing phagophore, or oligomerised SQSTM1 (Fig. 1). These tools effectively degrade the intracellular, extracellular, and membrane proteins, protein aggregates, lipid droplets, and damaged organelles. Moreover, it has been shown that pathologic proteins can be directly recruited to the 26S proteasome and subjected to induced proteolysis using small molecules, such as the recently developed Chemical Inducers of DEgradation (CIDE)⁵⁵ and Ub-Independent Degraders (UIDs).⁵⁶ Here, we overview recent developments in these TPD technologies that directly engage with the lysosome or the proteasome and outline a comprehensive analysis of each technique, including its strengths and limitations from both chemical and biological perspectives. Please note that this review uses the official human

gene/protein names, determined by the HUGO gene nomenclature committee (<https://www.genenames.org/>).

2. Targeted degradation of intracellular proteins and organelles through the autophagy machinery

2.1. AuTophagy-TEthering compounds (ATTECs)

One of the initial Ub-independent TPD methodologies was designed to utilise LC3 ligands that directly interact with developing phagophores in the early stage of autophagy (Fig. 2(A)). As only a limited number of LC3 ligands were available, compared to the wide array of existing ligands for E3 enzymes in PROTACs, Li *et al.* screened chemical libraries in a high-throughput setting to identify compounds that could



bind to LC3 and pathologic huntingtin (HTT) proteins simultaneously.⁴⁹ The length of polyglutamine (polyQ) in HTT is known to be proportional to its aggregation propensity in Huntington's disease (HD).⁵⁷ To selectively target the mutant HTT (mHTT) with long polyQ repeats such as HTT with 72 polyQ (HTT-Q72), they conducted a negative selection process to remove hit compounds interacting with non-pathological HTT-Q25. Interestingly, mHTT has been known to evade the UPS-mediated degradation, being preferentially cleared by autophagy,^{58–60} consistent with the prevailing notions about proteasomal degradation: (1) biased sequences, such as lengthy polyQ repeats, can impede proteasomal degradation of mHTT and (2) efficient degradation by the 26S proteasome necessitates a structurally disordered region in the substrate.^{61–63}

The lead ATTEC molecules, capable of binding to both LC3 and HTT-Q72, but not to HTT-Q25, possessed a lactam-based bicyclic structure with a halogen-substituted aryl group as a common structural motif (Table 1). Treatment with 100 nM of each ATTEC compound for 48 h potently decreased the levels of mHTT by 26–40% of maximal protein degradation (D_{Max}) in primary cortical neurons isolated from a knock-in mouse expressing mHTT-Q140 (ESI,† Table S1; for quantitative values in experimental conditions and assay read-outs).⁴⁹ In contrast, these compounds did not affect the levels of wild-type (wt) HTT-Q7. The analyses of global proteome in cultured cells and mice using mass spectrometry (MS) indicated that the levels of endogenous autophagic substrates, other than mHTT, remained largely comparable before and after the exposure of cells to ATTECs, demonstrating that the overall autophagic flux remained virtually unaffected (ESI,† Table S2).⁴⁹

Despite their bispecific binding properties, the sizes of these ATTECs were relatively small, being only 256–521 Da, similar to those of MGDs rather than PROTACs. Nevertheless, unlike MGDs, the majority of ATTECs displayed a “hook effect”, characterized by a diminishing effectiveness of a functional molecule beyond a certain dosage level. This phenomenon is

frequently manifested in heterobivalent TPDs due to the formation of stable binary structures with either the target protein or E3 ligase at the oversaturated concentration range.⁴⁹ At their effective concentrations, they significantly facilitated intracellular binding between mHTT and LC3. Moreover, ATTEC-dependent mHTT degradation was reversed either by lysosomal inhibitors (NH_4Cl or chloroquine) or *via* ATG5 silencing (essential for autophagosome formation), suggesting that the autophagy-tethering effect of ATTEC was responsible for the targeted degradation of mHTT. Nevertheless, a deeper understanding is required to clarify the mechanism whereby these small molecules differentiate between wt HTT and mHTT. It is also notable that pathologic mHTT typically accumulates and aggregates in the nucleus,^{64,65} while autophagy occurs only in the cytoplasm.

ATTECs were also tested in fibroblasts and iPSC-derived neurons from patients with HD and healthy individuals. While the wt HTT levels in fibroblasts from healthy groups were not affected, a significant reduction in mHTT levels was apparent in HD fibroblasts.⁴⁹ Additionally, the iPSC-derived neurons showed reduced mHTT levels when they were treated with the ATTEC compounds. The potential therapeutic effects of ATTECs have also been investigated in several *in vivo* models. In the inducible *Drosophila* model overexpressing mHTT-Q128, the flies treated with 10 μM ATTECs for six days showed significantly reduced mHTT levels and neurotoxicity as well as an extended lifespan.⁴⁹ In the $\text{Hdh}^{\text{Q7/Q140}}$ mouse model, the mice injected daily with ATTECs for two weeks (intraperitoneal or ip, 0.5 $\text{mg kg}^{-1} \text{day}^{-1}$) exhibited significant improvements in HD-related behavioural deficits.²⁶ Both wt flies and mice displayed no apparent impacts in response to the ATTECs, which implicates the minimal off-target effects and the potential of this autophagy-mediated technology for the TPD of other aggregation-prone proteins.

The ATTEC platform has several similarities to AUtophagy-TArgeting Chimeras (AUTACs), both designed to mediate the autophagic degradation of target proteins. Arimoto *et al.* exploited a derivative of *S*-guanine, *p*-fluorobenzylguanine, as a stand-alone degradation tag inducing Lys63-linked polyUb chains on targets.⁶⁶ AUTAC compounds linking this degradation tag and a substrate-targeting ligand could induce autophagic degradation of various proteins and mitochondria. While the degradation potential of the AUTAC platform has been demonstrated, the precise molecular mechanism underlying the action of *S*-guanine or its chemical analogue in generating Lys63-linked polyUb chains remains to be further elucidated.

Fu *et al.* attempted to expand the scope of the ATTEC technology; they developed heterobivalent ATTECs comprising LC3- and lipid droplet (LD)-binders *via* linkers with varying sizes and types (molecular weights ranging from 745 to 1040 Da; Table 2).⁶⁷ These LD-ATTECs effectively eliminated LDs in oleic acid-treated tumour cells and cultured adipocytes (at a concentration of 5 μM for 24 h) as well as in the liver of mouse models of hepatic lipidosis (ip injection, 30 $\text{mg kg}^{-1} \text{day}^{-1}$, once a day for 2 weeks) in an autophagy-dependent manner.⁶⁷ These results are one of the first demonstrations that non-proteinaceous




Fig. 2 The mechanism of actions of autophagy-based degraders, such as autophagy-tethering compound (ATTEC; A) and autophagy-targeting chimera (AUTOTAC; B). While ATTECs engage with LC3, which is essential for autophagosome biogenesis and maturation, AUTOTACs interact with an autophagic receptor SQSTM1/p62, which undergoes self-oligomerization with cargoes to be directed to autophagosomes. ZZ; the ZZ domain in SQSTM1, which directly interacts with the AUTOTAC compounds.



Table 1 Representative structures of Ub-independent TPD degraders. Their target binders and key lysosome, autophagy, or proteasome recruiters are colored in red and blue, respectively (cont'd)








TPD technology	Characteristics of degraders	Chemicals or biologics	Target recognition by	Structure	Molecular weight	Target substrates	Ref.
ATTEC	Chemicals	Ligands		<p>Molecular glue-type</p>  <p>1005, 8F20, AN1, AN2</p>	256–521 Da	mHTT, mutant ATXN3, polyQ-GFP	Z. Li (2019) ⁴⁹
				<p>LC3B — Linker — TBL</p>  <p>LC3B = 1005, 8F20, AN2</p> <p>TBL = JQ1 (BRD4), MS2 (NAMPT), SNS-032 (CDK9)</p>	641–1150 Da	BRD4, NAMPT, CDK9/cyclin T1	J. Pei (2021), ⁷² G. Dong (2022), ⁷³ and Y. Zeng (2023) ⁷⁴
				<p>LC3B =</p>  <p>LC3 binders</p> <p>Lipid droplet binder</p> <p>R = H or Me</p>	745–1040 Da	Lipid droplets	Y. Fu (2021) ⁶⁷
				 <p>LC3 binder</p> <p>Mitochondria binder</p>	683 Da (post-click)	Mito-chondria	M. Liu (2023) ⁶⁹
AUTOTAC	Chemicals	Ligands		<p>ATL — Linker — TBL</p>  <p>ATL =</p> <p>SQSTM1-binders</p> <p>TBL = PHTPP (ERβ), VinclozolinM2 (AR), Fumagilin (MetAP2)</p>	783–945 Da	ERβ, AR, MetAP2	C. H. Ji (2022) ⁵¹
				<p>ATL — Linker — TBL</p>  <p>ATL =</p> <p>SQSTM1-binders</p> <p>TBL = PBA, Anle138b</p>	625–817 Da	Aggregation prone proteins (desmin, tau, HTT, α-synuclein)	C. H. Ji (2022) ⁵¹ and J. Lee (2023) ⁸²
				<p>CXC12 chemokine</p>  <p>Target-binding Fab</p>	~140 kDa	VEGF, TNF-α, PD-L1, HER2, EGFR, PD-1, CDCP1, TROP2	K. Pance (2023) ⁵²



Table 1 (continued)






















		Characteristics of degraders					
TPD technology	Chemicals or biologics	Target recognition by	Structure	Molecular weight	Target substrates	Ref.	
LYTAC	Biologics	Antibodies	 Poly(M6Pn) glycopolymer 	> 500 kDa	mCherry, ApoE4, EGFR, CD-71, PD-L1	S. M. Banik (2020) ⁵⁰	
	Biologics	Antibodies	 CI-M6PR binder 	~ 152 kDa	EGFR, HER2	X. Zhang (2022) ¹¹⁹	
	Biologics or chemicals	Antibodies or ligands	 ASGPR-binding tri-GalNAc 	> 160 kDa	Rabbit IgG, Mouse IgG, EGFR, HER2, integrin	G. Ahn (2021) ¹²⁴ and Y. Zhou (2021) ¹²⁷	
	Chemicals	Ligands	 TBL =  D-MoDE-A  M-MoDE-A ASGPR-binding tri-GalNAc	1753–1788 Da	α -DNP antibody, MIF	D. F. Caianiello (2021) ¹²⁶	
	Biologics	Oligonucleotides	 Target-binding aptamer 	~ 33–47 kDa	Met, PTK-7, HER2	Y. Miao (2021) ¹²⁹ and K. Hamada (2023) ¹³⁰	
Biologics	Oligonucleotides	 Target-binding aptamer  ASGPR-binding tri-GalNAc	~ 17–21 kDa	PDGF, PTK-7	Y. Wu (2023) ¹³¹		
		Characteristics of degraders					
TPD technology	Chemicals or biologics	Target recognition by	Structure	Molecular weight (kDa)	Target substrates	Ref.	
IFLD	Chemicals	Ligands	 PD-L1 binder Integrin-binding cyclic RGD 	1290 Da	mCherry, ApoE4, PD-L1	J. Zheng (2022) ⁵³	
DENTAC	Chemicals	Oligonucleotides	 SR-binding DNA dendron Linker TBL =  aptamer  antibody (L) _{~2.5}	~ 22–180 kDa	nucleolin, EGFR	C. Zhu (2023) ⁵⁴	
CIDE	Chemicals	Ligands	 PSMD2 binder BRD4 binder 	2720 Da	BRD4	C. Bashore (2022) ⁵⁵	
UID	Chemicals	Ligands		838–926 Da	BRD2		



Table 1 (continued)

TPD technology	Characteristics of degraders		Structure	Molecular weight (kDa)	Target substrates	Ref.
	Chemicals or biologics	Target recognition by				
						M. Balzarini (2023) ⁵⁶

biomolecules can be selectively cleared by Ub-independent TPD. The LD-ATTECs were also evaluated in mouse models of age-related macular degeneration (AMD),⁶⁸ where a key pathological condition is the presence of drusen, the LD-containing deposits, in the retinal pigment epithelium. Intravitreal administration of LD-ATTEC in AMD model mice, once a week for 4 weeks, significantly reduced LD levels and delayed cytotoxicity and photoreceptor dysfunction in the retinal tissues.⁶⁸ The LD-ATTEC study highlights the distinct advantage of autophagic degraders, particularly when compared to PROTACs, *i.e.*, autophagic degraders can degrade not only soluble proteins but also aggregation-prone proteins and non-proteinaceous entities.

The range of potential ATTEC substrates has been broadened to include cellular organelles. The Qin group has developed mitochondria-targeting ATTECs, known as bio-ATTEC and mito-ATTEC, which combines an LC3 binder and the established mitochondrion-targeting motif, triphenylphosphonium cation.^{69,70} To minimise potential off-target effects, they utilised split ATTEC fragments with complementary click chemistry handles (azide and alkyne), allowing selective activation within the target cells. In bio-ATTECs, tissue specificity was achieved by employing cancer cell-specific surface antigen-binding aptamers. Specific aptamers, which are short single-stranded DNA or RNA nucleotides that fold into specific three-dimensional structures, are considered an effective alternative to antibodies and can be readily selected using an *in vitro* screening technique, called systematic evolution of ligands *via* exponential enrichment (SELEX).⁷¹ The authors observed mitochondrial depletion and autophagic tumour cell death after treatment with bio-ATTEC.⁶⁹ It would be intriguing to find out which specific mitochondrial proteins are initially engaged with the bio-ATTEC degrader. In addition, more warheads and linkers should be assessed for further validation and generalisation of this modality.

Following the discovery of potent LC3 binders, numerous efforts have been made to harness autophagy for targeted intracellular protein degradation. Recent studies have reported several ATTECs targeting bromodomain-containing protein 4 (BRD4),⁷² nicotinamide phosphoribosyltransferase (NAMPT),⁷³ and the cyclin-dependent kinase 9 (CDK9)/cyclin T1 complex.⁷⁴ The optimised BRD4-ATTEC exhibited impressive degradation activity (D_{Max} 92%, DC_{50} 0.9 μM) in MDA-MB-231 breast cancer cells, which have the highest level of PD-L1, without apparent disturbance in cellular autophagy flux. The significantly reduced

c-Myc expression, a key indicator of BRD4 inhibition, and potent anti-proliferative effects on various cancer cell lines following treatment with BRD4-ATTECs indicate that the LC3-engaging degraders could be a promising strategy for developing anti-cancer agents targeting BRD4. Zeng *et al.* made a noteworthy observation that CDK9-targeting ATTECs exhibit superior degradation and anti-proliferative activities compared to the corresponding CDK9-PROTACs, which share the same CDK9 binder.^{74,75} In addition, these ATTECs not only induced CDK9 degradation but also led to the degradation of CDK9-associated cyclin T1, which was not observed with the corresponding PROTAC. This collateral degradation implicates not only distinct mechanisms but also potentially different outcomes between these two approaches, although further comparative studies are necessary to fully grasp the respective strengths and limitations of each method. Nonetheless, the aforementioned results convincingly demonstrated the unique capability of the ATTEC platform to target a wide range of cellular components in a tissue-specific and autophagy-dependent manner.

2.2. AUTophagy-Targeting chimera (AUTOTAC)

Proteotoxic proteins, often found to be misfolded and aggregated, are known to disrupt normal cellular metabolism and, potentially, lead to cell death.⁷⁶ The abnormal accumulation of proteotoxic proteins can arise from (1) self-oligomerisation acquired from mutations or PTMs (a protein-centric view), (2) compromised clearance due to dysfunctional UPS or autophagy (a proteolysis-centric view), or (3) a combination of both (a synergistic mechanism).^{77–79} Numerous neurodegenerative diseases, including HD, Alzheimer's (AD), and Parkinson's (PD) disease, feature protein aggregates as one of their key pathogenic hallmarks. Once considered undruggable, these proteins have gained considerable attention as targets of TPD drugs. Several studies have proposed that while the UPS is responsible for clearing the soluble forms of proteotoxic proteins, particularly during the early stage of neurodegeneration, autophagy-mediated protein degradation becomes critical as proteotoxic proteins begin to get fibrillised in neurons.⁸⁰ To pharmacologically modulate this process, Ji *et al.* developed innovative autophagic degraders that exploit key components of the N-degron pathway (Fig. 2(B)).^{81,82}

In the N-degron pathway, formerly known as the "N-end rule" pathway, the *in vivo* half-life of a protein is primarily determined by its N-terminal amino acid.^{83,84} In the initial



Table 2 Degradation mechanisms, target proteins, and other characteristics of Ub-independent TPD degraders

TPD technology	Degradation mechanism		Targets degraded by	Target proteins		
	Degradation initially mediated by	Hijacking cellular mechanisms		Target protein types	Substrates tested	Ref.
ATTEC	LC3 binding ligands	Macroautophagy	Autophagy	Intracellular	mHTT, mutant ATXN3, polyQ-GFP, BRD4, NAMPT, CDK9/cyclin T1	Z. Li (2019), ⁴⁹ J. Pei (2021), ⁷² G. Dong (2022), ⁷³ and Y. Zeng (2023) ⁷⁴
				Intracellular organelle	Lipid droplets	Y. Fu (2021) ⁶⁷
				Intracellular organelle	Mitochondria	M. Liu (2023) ⁶⁹
AUTOTAC	ZZ domain of SQSTM1/p62-binding ligands	SQSTM1/p62 oligomerization by ATL	Autophagy	Intracellular	ER β , AR, MetAP2, aggregation-prone proteins (desmin, tau, HTT, α -synuclein)	C. H. Ji (2022), ⁵¹ Y. Lee (2023), ⁹⁰ and J. Lee (2023) ⁸²
				Intracellular pathogen	Intracellular bacteria	
LYTAC	M6Pn	M6Pn: CI-M6PR-mediated endocytosis	Lysosome	Extracellular	mCherry, ApoE4	S. M. Banik (2020) ⁵⁰ and X. Zhang (2022) ¹¹⁹
	tri-GalNAc	tri-GalNAc: ASGPR-mediated endocytosis		Membrane	EGFR, HER2 CD-71, PD-L1	G. Ahn (2021), ¹²⁴ D. F. Caianiello (2021), ¹²⁶ and Y. Zhou (2021) ¹²⁷
	CI-M6PR binding aptamers	Aptamer: CI-M6PR-mediated endocytosis		Extracellular	PDGF	Y. Miao (2021) ¹²⁹ and K. Hamada (2023) ¹³⁰
	ASGPR binding aptamers	Aptamer: ASGPR-mediated endocytosis		Membrane	PTK-7	Y. Wu (2023) ¹³¹
IFLD	Integrin binding cyclic RGD peptides	RGD peptide: integrin-mediated endocytosis	Lysosome	Extracellular	mCherry, ApoE4, PD-L1	J. Zheng (2022) ⁵³
DENTAC	Scavenger receptor binding DNA dendron	DNA dendron: SR-mediated endocytosis	Lysosome	Membrane	PD-L1	C. Zhu (2023) ⁵⁴
KineTAC	CXCL12	CXCL12: CXCR7-mediated endocytosis	Lysosome	Extracellular	VEGF, TNF- α	K. Pance (2023) ⁵²
				Membrane	PD-L1, HER2, EGFR, PD-1, CDCP1, TROP2	
CIDE	PSMD2 binding macrocycles	Proximity to AAA+ unfoldases	Proteasome	Intracellular	BRD4	C. Bashore (2022) ⁵⁵
UID	ADRM1-Halotag7 binding ligand	Proximity to 26S proteasomes	Proteasome	Intracellular	BRD2	M. Balzarini (2023) ⁵⁶

N-end rule, each amino acid within the genetic code was categorised into either “stabilizing” (including the start codon Met) or “destabilizing” (including positively charged Arg) residues for proteasomal degradation; however, it is now understood that all 20 amino acids can serve as N-degrons.⁸³ One of the key biochemical processes that generates an N-degron substrate is the conjugation of Arg to the N-terminus of a protein.⁸⁵ A set of ER-residing chaperons was reported to be N-terminally arginylated and retro-translocated to the cytosol, where the chaperons were bound to their new clients—cytosolic misfolded proteins. These complexes were then recognised by the autophagic adaptor SQSTM1 through its ZZ domain.^{86,87} This process involves the conformational change and self-oligomerisation of SQSTM1 for the delivery of cargoes (N-degrons) to autophagosomes.^{88,89} Therefore, N-terminal Arg functions not only as a binding site for E3 Ub ligases for ubiquitination but also as an activating ligand for SQSTM1 for activating autophagy.^{89–91} In the same context, SQSTM1 also has a dual role: as a prototype autophagic cargo adaptor and a novel N-recognition of destabilizing N-terminal residues.

AUTOTAC degraders are bispecific molecules linking a target-binding ligand (TBL) and an autophagy-targeting ligand that binds to the ZZ domain of SQSTM1.⁵¹ Using 3D structural modelling and structure–activity relationship studies, Chamolstad *et al.* developed Arg-based SQSTM1 ligands featuring

O-benzylated phenol or catechol moieties (Table 1).⁸⁷ These compounds induced conformational activation of SQSTM1, transforming it into an autophagy-compatible oligomer. Therefore, these ZZ ligands essentially mimic the biochemical action of the “destabilizing” residues in the autophagic N-degron pathway. AUTOTAC degraders were then synthesized by conjugating the ZZ ligands to diverse TBLs, such as PHTPP (a nonsteroidal antagonist of the oestrogen receptor β [ER β]), vinclozolin M2 (an androgen receptor [AR] blocker), and fumagillin (a ligand for methionine aminopeptidase 2 [MetAP2]) (Table 2).^{92–94} The effectiveness of these AUTOTAC compounds was demonstrated by achieving significant autophagic degradation of the cognate oncoproteins, such as ER β , AR, and MetAP2, within the sub-micromolar ranges of half-degrading concentration values (DC₅₀).⁴³ Importantly, these activities were completely abolished by silencing either *SQSTM1* or *ATG5*.⁵¹

To assess whether these AUTOTAC degraders can degrade aggregated proteins, additional compounds were synthesized to incorporate TBLs that recognise exposed hydrophobic motifs, a common structural property of misfolded proteins. The following TBLs were conjugated to the ZZ ligands: (1) 4-phenylbutyric acid (PBA), an FDA-approved drug and a chemical chaperone that binds to hydrophobic residues, and (2) Anle138b, an inhibitor of α -synuclein aggregation.^{95–97} In these studies, the PBA and Anle138b moiety-conjugated



AUTOTAC compounds (PBA-1105 and ATC161/Anle138b-F105) were effective in reducing the levels of mutant desmin, aggregation-prone tau-P301L, and mHTT, respectively.^{98–100} Remarkably, they did not affect the levels of non-pathologic counterparts such as wt desmin, tau, and HTT. The DC₅₀ values for the mutant tau and HTT proteins ranged from 1–10 nM and 0.1–1 μM, respectively, and a hook effect was observed at high concentrations (ESI,† Table S3).⁴³ For the *in vivo* evaluation, ZZ-PBA compounds were administered (ip injection, 20 or 50 mg kg⁻¹, 3 times per week for 1 month) to transgenic mice overexpressing hTauP301L tagged with bi-molecular fluorescence complementation (BiFC).^{101,102} Immunoblotting, immunostaining, and histochemical analyses showed reduced levels of RIPA-insoluble human hTauP301L and a decrease in BiFC fluorescence signal in the mouse brains.

The AUTOTAC platform was utilised to facilitate the autophagic clearance of intracellular bacteria and α-synuclein.^{82,90} As a part of their defence mechanisms, eukaryotic cells often rely on xenophagy, a type of selective autophagy, to capture intracellular pathogens, such as bacteria, protozoans, and viruses.^{103,104} However, these intracellular pathogens have also evolved to evade or even inhibit cellular xenophagy to survive within their host cells.^{105,106} The Kwon group discovered that treatment with SQSTM1-targeting ZZ ligands lacking TBL moieties was sufficient to induce the degradation of intracellular bacteria in cells and mice infected with *Salmonella enterica* and *Mycobacterium tuberculosis*.⁹⁰ Recently, Lee *et al.* introduced new TBLs in the AUTOTAC toolkit, including baicalein (ATC162), a flavonoid compound that binds to α-synuclein, and resveratrol (ATC163), a phenol compound that binds to α-synuclein.⁸² In the PD mouse model (oral administration, 10 mg kg⁻¹, 5 times per week, for 16 weeks), ATC161/Anle138b-F105 treatment reduced the number of α-synuclein aggregates in the brain, resulting in a significant delay in motor neuron degeneration. Similar to tau and α-synuclein, many target proteins tested with AUTOTAC degraders were either transiently or constitutively overexpressed. While it is a common practice to study proteotoxicity through transiently overexpressed proteins, a thorough evaluation of the overall efficacy for endogenous substrate proteins is crucial for a more accurate assessment of the therapeutic potential of the AUTOTAC technology. Furthermore, it also remains to be determined whether the AUTOTAC-induced oligomeric SQSTM1 captures off-target soluble proteins (potentially through phase separation)¹⁰⁷ and organellar membrane proteins (*via* direct phagophore binding)¹⁰⁸ at the proteomic level.

3. Targeted degradation of secreted and membrane proteins through the endolysosomal pathway

3.1. Lysosome-Targeting chimeras (LYTACs)

The initial non-Ub TPD degraders, including ATTECs and AUTOTACs, were designed for degrading intracellular proteins,

although over one-third of protein-encoding genes produce secreted and membrane proteins.^{37,109} First developed by the Bertozzi's group, the LYTAC technology mediates the lysosomal degradation of these proteins.⁵⁰ The original LYTAC molecules consisted of a substrate targeting antibody and a glycopolypeptide ligand for binding to the cation-independent mannose-6-phosphate (M6P) receptor (CI-M6PR; Fig. 3(A)). CI-M6PR is a plasma membrane-residing and endosome-targeting receptor that recognises *N*-glycans capped with M6P moieties.¹¹⁰ In addition, it functions as a decoy receptor, continuously shuttling M6P-modified cargoes from the plasma membrane to the endosomal compartments.^{111–114} In late endosomes and lysosomes, the low pH induces the dissociation of the endocytosed CI-M6PR and LYTAC-target complex and facilitates receptor recycling, while the target proteins are degraded in the lysosome.⁵⁰

To generate glycopolypeptides that are not only recognised by CI-M6PR but are also resistant to cellular phosphatase activity, Banik *et al.* synthesised *N*-carboxyanhydride (NCA)-derived Ser-Ala polypeptides (with various lengths) containing multiple serine-*O*-mannose-6-phosphonate moieties (M6Pn) (Table 1). The oxygen at the 6-position of mannose was replaced by the methylene linkage (CH₂) to improve their metabolic stability.⁵⁰ These M6Pn glycopolypeptides, unlike those containing mannose or *N*-acetylgalactosamine (GalNAc), successfully promoted the CI-M6PR-mediated uptake of cargo molecules by acidic endosomes and lysosomes in several cell lines.⁵⁰ Using CRISPR/Cas9-knockout screening, it was found that *IGF2R* (insulin like growth factor 2 receptor, an alternative gene name for *CI-M6PR*) and several genes involved in protein neddylation and activation of the E3 ligase cullin-3 (*CUL3*) are essential for the cargo uptake and LYTAC recycling.¹¹⁵ These results provided not only an unbiased validation of the underlying molecular mechanism of LYTACs but also a potential indicator (*e.g.*, neddylation of *CUL3*) to predict whether and to what extent LYTAC therapy will be effective *in vivo*.

To further validate this technology, the cellular uptake and degradation of apolipoprotein E4 (ApoE4), an extracellular protein that represents the most common genetic risk factor for AD, by a LYTAC molecule was tested (Table 2).¹¹⁶ First, a compound consisting of M6Pn-bearing glycopolypeptides conjugated to a goat anti-mouse IgG antibody (Ab-1) was developed. The conjugation involved random introduction of azide moieties onto multiple IgG lysine residues, followed by a copper-free, strain-promoted cycloaddition reaction with the bicyclononyne-bearing M6Pn ligand. Next, K562 lymphoblast cells were treated with 25 nM Ab-1 in the presence of both recombinant ApoE4 proteins and a mouse anti-ApoE4 antibody labelled with Alexa Fluor-647. The uptake of ApoE4 was increased by 13-fold following Ab-1 treatment. When leupeptin, an endolysosomal protease inhibitor, was co-treated with Ab-1 in the presence of mouse anti-ApoE4 antibodies, the intracellular levels of ApoE4 significantly increased, demonstrating the LYTAC-mediated lysosomal degradation of extracellular proteins. The LYTAC technology has also been utilised to directly target the epidermal growth factor receptor (EGFR) by conjugating the M6Pn glycopolypeptides to cetuximab, an EGFR-



targeting antibody (Ab-2). Treatment with 10 nM Ab-2 for 24–48 h resulted in effective degradation of EGFR on the surface of breast and liver cancer cells, reaching a 61–83% D_{Max} (ESI,† Table S4).⁵⁰ Quantitative proteomic analysis demonstrated that this LYTAC-mediated EGFR degradation was more specific than the cetuximab treatment alone (ESI,† Table S2).

A similar LYTAC-mediated degradation was observed by targeting other membrane-bound proteins, such as transferrin receptor 1 (CD71) and programmed death-ligand 1 (PD-L1), using Ab-1 LYTAC (with a polyclonal anti-mouse IgG) co-treated with mouse anti-CD71 antibodies in EGFR-negative cells and Ab-3 LYTAC (with a monoclonal anti-PD-L1 antibody, atezolizumab) in PD-L1-positive cells, respectively.^{117,118} As observed previously,⁵⁰ treatment with antibodies alone without glycopolypeptides did not have a significant effect on the target protein levels. Moreover, degradation was abolished when cells were treated with competing M6P or lysosome inhibitors, further confirming the mechanism of LYTAC action. Mice injected with the M6Pn-cetuximab conjugate (single injection, 5 mg kg⁻¹) exhibited a two-phase (first rapid and then sustained) clearance of the LYTAC molecule.⁵⁰ Since EGFR, CD71, and PD-L1 are all promising targets in cancer therapy, the LYTAC modality may represent a complementary or synergistic platform to conventional chemotherapy. However, the poor metabolic stability of these M6Pn-conjugated antibodies *in vivo* still needs to be improved to enhance their possible therapeutic benefits as anti-tumour agents.

Given the relatively long half-lives (> 3 days) of cetuximab and atezolizumab, the rapid clearance of LYTACs in the circulatory system might result from the heteropolymorphic nature of the M6Pn glycopolypeptide ligand. The lack of site-specific conjugation of M6Pn to antibodies is also expected to contribute to this pharmacokinetic characteristic. More recently, Zhang *et al.* developed a chemoenzymatic method to prepare homogeneous CI-M6PR-targeting LYTACs.¹¹⁹ Based on their prior observation that simple glycans may possess high affinity

for CI-M6PR with mannose-6-phosphate- α 1,2-mannose disaccharide moieties, antibodies were modified with minimal M6P glycans (tri- or tetra-saccharides) instead of glycopolypeptides. The site-specific introduction of the M6P motif to the antibody was accomplished by using engineered endoglycosidases that function as a transglycosylation catalyst. This approach enabled the generation of homogeneous LYTACs that targeted EGFR and HER2, with their *in vitro* proteolytic activities being comparable to those achieved using polymeric M6Pn ligands. Nevertheless, whether the homogeneous structure of LYTAC antibodies improves their pharmacokinetic profiles *in vivo* remains to be determined.

In their second LYTAC study, Bertozzi and co-workers used the asialoglycoprotein receptor (ASGPR), which is another endosome-targeting receptor exclusively expressed in the liver, as opposed to the ubiquitously expressed CI-M6PR.^{120,121} ASGPRs can recognise the galactose or GalNAc moieties on extracellular proteins and internalize them *via* clathrin-mediated endocytosis for lysosomal degradation.¹²² Specifically, a triantennary GalNAc (tri-GalNAc: 1.7 kDa) motif was exploited as an ASGPR-targeting ligand for LYTAC development, as it has been widely used as a vehicle for the targeted delivery of oligonucleotides into hepatocytes *via* ASGPRs.¹²³ For proof of concept, tri-GalNAc was conjugated with a targeting ligand such as a synthetic polyspecific integrin-binding peptide (PIP: 3.4 kDa) as an alternative to antibodies (Fig. 3(A) and Table 1).¹²⁴ The treatment of HEPG2 cells with tri-GalNAc-PIP resulted in a significantly facilitated degradation of cell-surface integrins and delayed cell proliferation. Similarly, the tri-GalNAc-cetuximab conjugate selectively degraded cell-surface EGFRs in HEP3B, HEPG2, and HUH7 cells ($DC_{50} \approx 1$ nM), but not in non-hepatocellular carcinoma cell lines (ESI,† Table S4). Tri-GalNAc-pertuzumab conjugates also degraded ~75% of total HER2 in HEPG2 cells, while pertuzumab alone reduced the HER2 levels by only ~30%. Notably, these conjugates featured a single tri-GalNAc ligand, which was attached at specific locations utilising the SMARTag technology.¹²⁵ *In vitro*




Fig. 3 Lysosome-based degraders which utilise ligand-triggered receptor endocytosis, such as lysosome-targeting chimera (LYTAC; A), molecular degraders of extracellular proteins through the ASGPR (MoDE-A; A), integrin-facilitated lysosomal degradation (IFLD; B), dendronized DNA chimera (DENTAC; C), and cytokine receptor-targeting chimeras (KineTAC; D). Other similar platforms based on bifunctional antibodies, including TranstAC and EndoTag, have recently reported.



degradation assays revealed that the activity of the HER2-targeting LYTAC with a hinge modification was comparable to that of the non-specific counterpart, having more than 10 equivalents of the tri-GalNAc ligands. When homogeneous EGFR-targeting LYTACs were administered to mice for a week (ip injection, 5 mg kg⁻¹, every 2 or 4 days), site-specific LYTAC conjugates showed sustained *in vivo* stability; by contrast, non-specific heterogeneous conjugates underwent rapid clearance. This observation may exemplify the significance of homogeneous antibody modifications in elevating metabolic stability *in vivo*.

A key advantage of employing ASGPRs over CI-M6PR lies in their structural uniformity of the receptor-targeting motif, tri-*N*-GalNAc, and structural flexibility, which allows further functional optimisation. Almost simultaneously with Bertozzi's report on ASGPR-based LYTACs,¹²⁴ Spiegel's and Tang's groups independently reported their TPD strategies, which also capitalized on the ASGPR and tri-GalNAc interactions (Table 1).^{126,127} Tang's design was based on the conjugation of tri-GalNAc to antibodies or antigen-binding fragments (Fabs), akin to Bertozzi's concept, whereas Spiegel *et al.* pursued a fully synthetic molecular approach akin to the tri-GalNAc-PIP concept, resulting in MoDE-A (MOlecular DEgraders of extracellular proteins through ASGPRs).¹²⁶ They connected the ASGPR-binding tri-GalNAc motif to either a dinitrophenyl (DNP) group or the inhibitor of the cytokine macrophage migration inhibitory factor (MIF), which resulted in the formation of two distinct compounds—D-MoDE-A and M-MoDE-A (Fig. 3(A)). These derivatives effectively formed corresponding ternary complexes with ASGPR and their cognate targets, leading to the lysosomal degradation of α -DNP antibodies and MIFs, respectively. Moreover, M-MoDE-A effectively reduced the levels of exogenously administered human MIF in the sera of nude mice (ip injection, 1 mg kg⁻¹ or 10 mg kg⁻¹ M-MODE-A), although the *in vivo* effects of these modalities on endogenous protein targets still remain to be validated. Moreover, although these LYTACs are likely to be recycled without being co-degraded with their target proteins, the quantitative analysis of the *in vivo* DC₅₀ and D_{Max} would be informative for attaining a comprehensive understanding of their pharmacological property and therapeutic efficacy.

Aptamers have further broadened the scope of LYTAC-mediated degradation of extracellular and membrane-associated proteins.¹²⁸ The following studies have been conducted to generate and utilise aptamer-conjugated LYTACs (also known as Apt-LYTACs): (1) bispecific DNA aptamers targeting both CI-M6PR and mesenchymal-epithelial transition receptor (Met) or protein tyrosine kinase-like 7 (PTK7),¹²⁹ (2) bispecific DNA aptamers targeting CI-M6MR and HER2,¹³⁰ and (3) tri-GalNAc-conjugated DNA aptamers targeting PTK7 or platelet-derived growth factors (PDGFs) (Table 2).¹³¹ Considering the rapid advancements in aptamer/carbohydrate chemistry and antibody engineering, the PIP-LYTAC, MoDE-A, and Apt-LYTAC molecules represent a novel class of efficient lysosome-based TPDs. Nevertheless, a more comprehensive understanding of lysosome homeostasis, especially under diverse disease conditions, appears to be imperative for these LYTAC molecules to achieve improved safety and effectiveness as therapeutics.

3.2. Related modalities: integrin-facilitated lysosomal degradation (IFLD) and DENdronised DNA chimera (DENTAC)

The LYTAC technology operates through ligand-triggered endocytosis and subsequent internalisation of target proteins to the lysosome. This opens up the potential for harnessing various analogous receptor–ligand pairs to drive the lysosomal degradation of extracellular and membrane-associated proteins. Integrins, which are known cell-to-cell adhesion receptors, are often overexpressed on various cancer cells and selectively interact with the Arg–Gly–Asp (RGD) peptides ($M_w = 619.7$ Da). The Li group introduced the IFLD platform, wherein the RGD motif is linked to neo-substrate-targeting small molecules or antibodies (Fig. 3(B)).⁵³ A conjugate composed of cyclic RGD and BMS-8, a small molecule PD-L1 binder, exhibited ~70% degradation activity at a 25 nM concentration in MDA-MB-231 cells. In an *in vivo* melanoma xenograft mouse model (iv injection, 5 mg kg⁻¹, every 2 days), these chimeric molecules led to significant tumour regression, accompanied by a notable decrease in PD-L1 levels in tumour tissues, as determined *via* immunohistochemistry analysis (ESI,† Table S5).

Another approach utilised cell-surface scavenger receptors (SRs) that bind to anionic ligands. These receptors have been used to facilitate the intracellular delivery of polyanionic DNA nanomaterials through caveolae-mediated endocytosis.^{132,133} Zhu *et al.* developed DENTACs by combining dendritic DNAs with target-binding motifs, either antibodies or aptamers, to mediate the SR-dependent TPD (Fig. 3(C)).⁵⁴ A specific DENTAC for nucleolin (NCL) was generated by conjugating polythymidine DNA dendrons to AS1411, a known NCL-binding DNA aptamer; it exhibited significant NCL degradation activity in A549 lung adenocarcinoma cells (with a DC₅₀ of 25 nM and D_{Max} of 60% at 50 nM). An *in vivo* study using an A549 mouse xenograft model (ip injection, 2 mg kg⁻¹, every 2 days for 2 weeks) also showed significant regression of tumour size (~76% reduction in weight) without apparent body weight loss (~76% reduction in weight) without apparent body weight loss (ESI,† Table S5). Recent reports in bioRxiv have suggested the potential of other naturally recycling receptors to redirect target proteins to lysosomal degradation, such as the transferrin receptor (TransTAC)¹³⁴ and sortillin (EndoTag).¹³⁵ While these findings are pending for evaluation, emergence of novel methods will broaden the array of lysosome-trafficking receptor and corresponding ligand pairs for alternative LYTAC modalities.

3.3. CytoKine receptor-Targeting chimeras (KineTACs)

Specific antibodies can be discovered relatively rapidly using well-established techniques such as phage display or optofluidic systems. Numerous PROTAC degraders have been covalently linked to monoclonal antibodies to enhance their tissue-targeting ability, a concept largely resembling the antibody–drug conjugate system.¹³⁶ For instance, the conjugation of trastuzumab to a BRD4-targeting PROTAC led to selective BRD4 degradation only in HER2-positive breast cancer cells.¹³⁷ In the GlueTAC platform, a PD-L1 nanobody was cross-linked to proximity-reactive, non-canonical amino acids, which enabled covalent binding of the nanobody to PD-L1 receptors.¹³⁸ The



GlueTAC nanobodies also retained a cell-penetrating peptide and a lysosome-sorting sequence, facilitating their internalisation and the subsequent lysosomal degradation of PD-L1. Cotton *et al.* developed the first bispecific antibody-based TPD platform, called Antibody-based PROTAC (AbTAC). The AbTACs are capable of recognizing both a target membrane protein and the membrane-bound E3 Ub ligase RNF43.¹³⁹ The AbTACs mediated target degradation by inducing polyubiquitination and subsequent trafficking of the cargo to the lysosome. By contrast, a similar bispecific antibody (PROTAB) recruiting zinc and ring finger 3 (ZNRF3), another cell-surface E3 ligase, has been demonstrated to degrade target substrates by 26S proteasomes.¹⁴⁰ Recently, the Wells group expanded their TPD platforms from AbTACs to KineTACs (Fig. 3(D)),⁵² both of which share a common architecture of bispecific antibodies. Unlike AbTACs, which target only membrane proteins due to their reliance on membrane-bound RNF43, KineTACs are capable of triggering the lysosomal degradation of both membrane and extracellular proteins *via* the endolysosomal pathway, similar to the LYTAC technology.

KineTACs achieved lysosome-mediated target degradation through cytokine-mediated endosome-targeting receptors. The knobs-into-holes method¹⁴¹ was adopted to generate recombinant antibodies with two distinct functional components—(1) human C-X-C motif chemokine ligand 12 (CXCL12) fused to the knob crystallizable fragment (Fc), which binds to the non-signalling chemokine receptor CXCR7, and (2) a Fab fused to the hole Fc domain (Table 1). KineTACs, similar to LYTACs, facilitated the lysosomal degradation of various proteins through the constant internalisation of CXCR7 with β -arrestin recruitment. The initial KineTAC bispecific antibody was generated to target PD-L1 by incorporating the Fab fragment of atezolizumab into the KineTAC scaffold. The treatment of different cancer cells with this CXCL12-atezolizumab chimera robustly reduced endogenous PD-L1 levels by $\sim 90\%$, which was a modestly higher reduction than that achieved by AbTAC ($\sim 63\%$ of D_{Max}).¹³⁹ In contrast, the atezolizumab Fab or CXCL12 isotype alone had little effect on PD-L1 levels. In addition to PD-L1, the KineTAC platform was applied to degrade other cell surface proteins, including HER2, EGFR, PD-1, CDCP1, and TROP2, by utilising trastuzumab, cetuximab, nivolumab, 4A06, and sacituzumab, respectively (Table 2).^{142–144} The landscape of the KineTAC targets has been further expanded to include soluble extracellular proteins, such as vascular endothelial growth factor (VEGF) and tumour necrosis factor α (TNF α). Specifically, chimeric CXCL12-targeting KineTAC antibodies, containing either bevacizumab or adalimumab, effectively induced the intracellular uptake and delivery of extracellular VEGF or TNF α to the lysosome; however, the degree of extracellular protein degradation by KineTACs remains to be assessed.

To evaluate the general applicability of KineTAC-mediated degradation, alternative chemokines (CXCL11 and vMIP1I, both targeting the CXCR7 chemokine receptor) were incorporated into their functional repertoire. The results indicated that these variants achieved degradation efficiencies comparable to those

of the original CXCL12-based KineTACs. KineTACs utilising the human interleukin-2 (IL-2) cytokine fused to nivolumab were also effective in degrading the cell surface PD-1 proteins (D_{Max} of 86.7%) (ESI,† Table S6), which suggested that this modality might not be restricted to CXCR receptors but rather exhibit broad versatility across various cytokine receptor-mediated internalisation systems. Intravenously administered CXCL12-trastuzumab showed promising pharmacokinetic characteristics in mice, such as prolonged circulation time and reduced cross-reactivity. However, the therapeutic potential of KineTAC antibodies can be validated only when their ability to induce efficient target degradation is demonstrated *in vivo*. Owing to their relatively simple engineering and production processes, KineTACs offer a compelling technical advantage over functionally analogous LYTACs, which usually involve complex synthesis and conjugation chemistry. Moreover, KineTAC production can avoid concerns such as light chain-heavy chain mispairing, a common issue encountered in bispecific IgG production.¹⁴¹ Considering the flexibility in leveraging various cytokine-receptor pairs as well as the robust *in vivo* stability, it seems evident that the application of the KineTAC platform can rapidly expand the TPD of therapeutically relevant proteins.

4. TPD by direct recruitment of the 26S proteasome

4.1. Chemical inducers of DEgradation (CIDes)

The 26S proteasome is the hybrid of an ancient unfolding-proteolysis machinery and a more recent polyUb-recognizing system, which are evolutionarily separated by billions of years. Chambered proteases in bacteria, such as ClpP, demonstrate remarkable structural and mechanistic similarities to the CP complex or 20S proteasome in archaea and eukaryotes.¹⁴⁵ Since prokaryotes lack Ub, they employ specific peptide sequences, most notably the *E. coli* SsrA, which are recognised by the AAA+ ATPase ClpX.¹⁴⁶ This AAA+ motor complex, arranged in a homohexameric ring, unfolds the substrates and translocates them through an axial channel into the catalytic chamber of ClpP complexes, which consist of two homoheptameric rings.¹⁴⁷ In eukaryotic cells, six AAA+ ATPase subunits (PSMC1 to PSMC6 from six different genes) form a heterohexameric ring on the base of the RP contacting the PSMA heteroheptameric ring of the CP.¹⁴⁸ The RP also plays a role in bringing in substrates to the CP using multiple Ub receptors, including a stoichiometric subunit PSMD2.³¹ It is largely accepted in the field that (1) Ub does not affect the thermodynamic stability of target proteins, (2) it only brings substrates into close proximity with 26S proteasomes, and (3) the direct recognition by the proteasome is usually sufficient for the substrates to be degraded in the CP.¹⁴⁹ Under these presumptions, direct tethering of substrates to proteasomes through bifunctional ligands could be a viable strategy to induce TPD, instead of altering the global proteome.

Bashore *et al.* in Genentech pioneered the direct proteasome targeting modality (referred to as CIDE) as an alternative TPD






Fig. 4 Degradation mechanisms. Panel A (CIDE) shows a POI-TBL complex binding to a PSMD2-binding macrocycle, which then directly engages the 26S proteasome for proteasomal degradation. Panel B (UID) shows a POI-TBL complex binding to an ADRM1-binding HaloTag7 ligand, which then directly engages the 26S proteasome for proteasomal degradation.

technology (Fig. 4(A)).⁵⁵ Their initial breakthrough was the identification of ligands that could specifically bind to the Ub receptor PSMD2. By screening both 8- to 16-amino acid-long peptide phage libraries and 10- to 14-residue macrocyclic mRNA display libraries, one peptide (PP1) and three macrocycles (MC1 to MC3) with strong affinities (in a nanomolar range) to a recombinant PSMD2 protein were identified. Biotinylated versions of macrocycle MC1, but not its enantiomeric controls, effectively pulled down 26S proteasomes without compromising their structural integrity. Cryo-EM images with a 2.5 Å-resolution unveiled that MC1 binds to the solenoid domain and C-terminal region of PSMD2, which are proximal to the AAA+ unfoldase or the PSMC APTase ring. To further enhance the versatility of MC1, a click chemistry-based approach was utilised to synthesise various versions of MC1 linked to BETi, a BRD4 ligand/inhibitor,¹⁵⁰ using PEG linkers with different lengths and conjugation sites (Table 1). These heterobifunctional MC1-BETi molecules were also able to strongly interact with PSMD2, forming a proper ternary complex with PSMD2 and BRD4 *in vitro*.

A fluorescence microscopy analysis revealed that CIDEs, despite their peptidic nature, can be internalized to the cytoplasm in an endocytosis-independent manner.^{151,152} In HEK293 cells, the most permeable MC1-BETi derivative (*L*-CIDE), but not its *D*-enantiomer, triggered significant and dose-dependent BRD4 degradation. This phenomenon was effectively abolished by proteasome inhibitors. Although the DC_{50} of *L*-CIDE remained relatively high at a concentration of 0.73 μ M (ESI,† Table S7), these results provided initial validation for the feasibility of TPD *via* the direct recruitment of the 26S proteasome. However, it remains uncertain whether the functionality of CIDE depends on or is affected by the presence of the polyUb chains on target substrates. This is implicated in the practicality of CIDE compounds in treating, for example, BETi-resistant cancer, where BRD4 is often poorly polyubiquitinated.¹⁵³ More CIDE compounds targeting other endogenous proteins besides BRD4 need to be developed and assessed to understand the mechanistic basis of this TPD modality. If CIDE molecules could enable Ub-independent degradation simply by bringing proteins close to 26S

proteasomes, these compounds could eliminate a wide range of cytosolic, nuclear, and membrane proteins, rendering CIDEs as more versatile TPD options than PROTACs.

4.2. ADRM1-mediated Ub-independent degraders (UIDs)

Recently, an alternative TPD strategy based on direct engagement of 26S proteasomes without involving polyUb chains was proposed by Kodadek *et al.*⁵⁶ The UID system employs ADRM1, another Ub receptor on the 26S proteasome, located approximately 107 Å away from the PSMC1-6 ATPases on the RP base.³¹ Since a suitable ligand for ADRM1 did not exist, a cell line stably overexpressing the N-terminal segment of ADRM1 fused to HaloTag7 was used as a model system and a primary chloroalkane chain conjugated to a substrate-targeting ligand was tested as a cognate UID compound (Fig. 4(B)). The prototype UIDs targeting the bromo and extra-terminal domain (BET) family proteins were synthesised to have varying lengths of ethylene glycerol linkers between the chloroalkane group and a BET bromodomain ligand, JQ1. Significant degradation of BRD2 was observed only when the length of these linkers exceeded four ethylene glycerol units (Table 2). Neither a HaloTag7 ligand nor JQ1 alone triggered proteasomal recruitment or BRD2 degradation. Although both BRD2 and BRD4 could be brought into close proximity to ADRM1 through JQ1-chloroalkane conjugates, only BRD2, but not BRD4, underwent substantial degradation. Similarly, heterobivalent molecules (ByeTACs), consisting of an ADRM1 binder and JQ1, induced a Ub-independent, proteasomal degradation of BRD4 in a nanomolar concentration range.¹⁵⁴ These findings need to be further validated but suggest that the recruitment of a target protein to the proteasome may be sufficient for effective degradation.

In contrast to the CIDE study,⁵⁵ which lacked detailed information regarding the involvement of substrate polyubiquitination, this study provided valuable insights into this question. In brief, the UID approach appeared to operate through a Ub-independent mechanism; while proteasome inhibitors significantly delayed Halo/UID-mediated TPD, E1 Ub activating enzyme inhibitors, which block the initial step of polyUb chain formation, did not affect the process.⁵⁶ Proteasome-based TPD modalities, which essentially create “neo-proximity” between the 26S proteasome and substrates, hold promise for opening new opportunities in drug discovery. However, it should be noted that the proteasome operates through highly coordinated multistep mechanisms, with peptide bond cleavage being only the last step in the complex program of substrate manipulation. Therefore, additional studies are needed to further evaluate the potential changes in global proteostasis resulting from direct proteasome-targeting methods such as CIDE and UID, especially considering that the direct proteasome-targeting ligands may act as an antagonist of proteasomal degradation. Additionally, the effectiveness of these approaches as targeted protein degraders needs validation through animal model studies. Once such data become available, they will provide a more comprehensive biochemical



framework for investigating the functionality, safety, and therapeutic applicability of these approaches.

5. Conclusions and perspectives

This tutorial review explores innovative technical platforms for degraders that do not rely on target ubiquitination and thus have considerably expanded the TPD target space (Fig. 1 and Table 1). The majority of TPD drugs currently undergoing clinical trials are PROTAC- and molecular glue-based degraders, utilising a very limited number of E3 Ub ligases.¹⁵⁵ In addition, these approaches require precise spatial control to facilitate coordinated interactions among E2, E3, and the target protein and subsequent induction of substrate ubiquitination. Direct recruitment of targets to the 26S proteasome may present an alternative strategy that overcomes several hurdles of PROTAC-based therapies, such as limited E3 availability (only CRL4^{CRBN} and CRL2^{VHL} recruiters have entered the clinical trials) and drug resistance (due to somatic mutations of the E3 ligases in cancer cells).^{156–158} The TPD modalities that directly harness the lysosomal degradation system have the potential to target an even broader spectrum of substrates, including extracellular proteins (Table 2). It is worth noting that many human proteopathies occur outside cells, rather than within the intracellular space, rendering them inaccessible by conventional E3-recruiting TPD strategies.¹⁵⁹ Our understanding of extracellular proteostasis is still limited. With the advancement in our knowledge of these mechanisms and pathological implications, leveraging lysosome/autophagy-based TPD approaches will fully unlock their therapeutic benefits.

A potential concern regarding lysosome/autophagy-based TPDs is the risk of unintended proteolysis of off-target substrates because early endosomes and growing phagophores intrinsically engage with a number of proteins or organelles. Moreover, selective autophagy relies on only a few autophagic receptors embracing a wide variety of intracellular cargoes; in contrast, the UPS utilises approximately 600 E3 ligases, each with some level of specificity for distinct substrates.¹⁶⁰ Thus, although these degraders are designed to meticulously discriminate their intended cargoes from other cellular components, it seems crucial to evaluate any potential alterations in the turnover rates of other endogenous substrates. For translating TPD technologies into therapeutic applications, a comprehensive global proteome analysis is crucial for a rigorous evaluation of potential on-site-off-targets as well as off-site-on-target effects.

Another important question is whether the action mechanism of lysosome-mediated TPD conforms to the event-driven pharmacology demonstrated by the catalytic and sub-stoichiometric mode of PROTACs or whether these lysosomal/autophagosomal degraders are irreversibly trapped in lysosomes along with their cargoes without recycling. From a biochemical standpoint, it is conceivable that degraders directly targeting 26S proteasomes (such as CIDEs, UIDs, and ByeTACs) are anticipated to be recycled similar to proteasomal Ub receptors and cellular Ub shuttle proteins. The small-molecule degraders targeting autophagosomes, such as

ATTECs and AUTOTACs, may rely on their stability within the lysosomal compartments as well as their capability to escape from lysosomal degradation. The chemical modality likely plays a significant role in recyclability. While antibody- or peptide-based degraders are highly susceptible to various hydrolases and acidic environments within the lysosomes, small molecule degraders are more likely to maintain structural integrity under those conditions for catalytic functionality. Nonetheless, all these speculations lack sufficient evidence, warranting more comprehensive studies in that regard.

Apparently, it is more challenging to quantitatively assess the enzyme kinetics and potencies of lysosome/autophagy-mediated degraders *in vitro*, compared to those of PROTACs, because the former are engaged with more cellular components (both proteins and lipids) than the latter in exploiting relatively well-defined E3 enzymes and proteasomes. Moreover, given the current technical limitations in measuring autophagic flux as well as endpoint autophagic activity, finding a therapeutic window for these degraders *in vivo* appears more difficult than for conventional drugs or PROTACs. The lysosome or autophagy inducers are required in relatively high dosages to achieve sufficient potency, where the positive “cooperativity” in ternary complex formation cannot mitigate the hook effect. Moreover, their pharmacological characteristics can be altered as the total catalytic output of cellular autophagy keeps changing according to the metabolic states and is tightly balanced with that of the UPS.^{161–163} Lysosome/autophagy-targeting degraders, combined with in-depth mechanism studies into their biochemical and physiological effects, could offer a promising alternative to UPS-targeting TPDs. Lysosome/autophagy-targeting degraders, after in-depth mechanism studies of their biochemical and physiological effects, could offer a promising alternative to UPS-targeting TPDs.

More recently, Forte *et al.* developed heterobifunctional molecules which can recruit an E2 Ub-conjugation enzyme, such as UBE2D, and induce specific protein degradation.¹⁶⁴ They also reported that the recruiters of a CUL4A adaptor protein DDB1 could be harnessed for effective TPD as well.¹⁶⁵ While these alternative strategies are intriguing, their mechanistic principles closely resemble those of PROTACs utilising the cellular UPS system. Therefore, it remains to be determined whether these novel approaches can offer distinct advantages over the E3 recruitment strategy. Since the human genome encodes ~40 E2 enzymes and E2s crosstalk with multiple E3 enzymes, E2-based degraders may target multiple substrates simultaneously. On the other hand, the direct guidance of disease-causing proteins to 26S proteasomes, as demonstrated by CIDE and UID technologies, stands out as a distinctive strategy, as it does not require polyubiquitination of target proteins. In the UPS-based proteolytic process, the delivery of polyubiquitinated substrates slated for proteasomal degradation solely relies on the ability of Ub receptors to aid their positioning in close proximity to the 26S proteasome. Thus, proteasome-recruiting compounds can essentially serve as faithful surrogates of polyUb tags. It is also possible that they may not require strict “cooperativity” to form a ternary



complex, as is the case with E3-recruiting degraders. By bypassing the ubiquitination steps and allowing more flexible ternary conformations, these degraders are likely to trigger the target degradation more efficiently than PROTACs. Moreover, the ubiquitous and abundant expression of proteasomes ($>10^6$ molecules per cell)¹⁶⁶ precludes many limitations of canonical PROTACs.

Considering that proteasomes are responsible for the proteolysis of at least 80% of cellular proteins ($\sim 3 \times 10^9$ total proteins in a growing mammalian cell),^{167,168} an important question that arises regarding the direct 26S proteasome recruiters is whether these affect the normal function of proteasomes. Moreover, since the 26S proteasomes have many distinct conformational states for processing their polyubiquitinated substrates (at least seven conformations in mammals),¹⁶⁹ the functionality of specific ligands may vary, for example, from the substrate-engaging states to degradation-competent states. The effectiveness of these modalities can also be compromised under various disease conditions, when an excess of substrates could “clog” the entry pore of the proteasome often observed in cancer and neurodegeneration. In such cases, the pharmacological enhancement of proteasomal activity, along with proteasome-recruiting degraders, could synergistically reverse the adverse effects caused by excess pathologic proteins. We anticipate that more proteasome-recruiting degraders, which exploit various subunits in the RP and CP, will be developed in the future through AI-guided drug designs. Nevertheless, their effects on proteasome mechanics, interactions with other proteins, and the impacts on the global proteome should be rigorously assessed. Furthermore, a quantitative evaluation of the binding affinity between CIDE compounds and their cognate proteasome subunits would be essential for fine-tuning the degradation kinetics. This is also important because compounds with an excessively high binding affinity towards the 26S proteasome might impede substrate translocation into its catalytic chamber for proteolysis.

The mechanistic and quantitative comparisons (ESI,† Tables S1–S7) presented in this review may serve as a practical guide for the future development and evaluation of non-Ub-mediated TPD modalities. For successful translational applications, we believe that the following assessments should be the standard practice in developing lysosome/autophagy- or proteasome-targeting degraders: (1) measuring the extent to which the degraders bind to the components of proteolytic machinery in test tubes (biophysical assessment), (2) determining whether targeted degradation is completely compromised with genetic knockout or chemical inhibitors of key components in cultured cells (biochemical evaluation), and (3) assessing the level of specificity they can achieve in animal models (proteomic validation). In-depth investigations following proof-of-concept studies are crucial to prevent the premature use of unverified degraders in pre-clinical or clinical applications. The strategies are still evolving, and we anticipate encountering unprecedented challenges both in the mechanistic understanding and pharmacological application. However, establishing validated approaches directly targeting lysosomes or proteasomes seems to remain a feasible and important goal, diversifying the

TPD strategies and offering an alternative route to address various human diseases. Classic biochemical studies on the UPS and autophagy have laid the foundation and provided the inspiration for the development of novel TPDs, a trend that will continue into the future.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the Samsung Research Funding & Incubation Center of Samsung Electronics (SRFC-MA2202-06 to M. J. L.).

References

- 1 L. Zhao, J. Zhao, K. Zhong, A. Tong and D. Jia, *Signal Transduction Targeted Ther.*, 2022, 7, 113.
- 2 X. Han, L. Zhao, W. Xiang, C. Qin, B. Miao, T. Xu, M. Wang, C. Y. Yang, K. Chinnaswamy, J. Stuckey and S. Wang, *J. Med. Chem.*, 2019, 62, 11218–11231.
- 3 D. P. Bondeson, B. E. Smith, G. M. Burslem, A. D. Buhimschi, J. Hines, S. Jaime-Figueroa, J. Wang, B. D. Hamman, A. Ishchenko and C. M. Crews, *Cell Chem. Biol.*, 2018, 25, 78–87.
- 4 J. L. Gustafson, T. K. Neklesa, C. S. Cox, A. G. Roth, D. L. Buckley, H. S. Tae, T. B. Sundberg, D. B. Stagg, J. Hines, D. P. McDonnell, J. D. Norris and C. M. Crews, *Angew. Chem., Int. Ed.*, 2015, 54, 9659–9662.
- 5 K. M. Sakamoto, K. B. Kim, A. Kumagai, F. Mercurio, C. M. Crews and R. J. Deshaies, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, 98, 8554–8559.
- 6 A. Bricelj, C. Steinebach, R. Kuchta, M. Gütschow and I. Sosič, *Front. Chem.*, 2021, 9, 707317.
- 7 L. Buetow and D. T. Huang, *Nat. Rev. Mol. Cell Biol.*, 2016, 17, 626–642.
- 8 A. Ciechanover, A. Orian and A. L. Schwartz, *BioEssays*, 2000, 22, 442–451.
- 9 G. Dong, Y. Ding, S. He and C. Sheng, *J. Med. Chem.*, 2021, 64, 10606–10620.
- 10 A. Domestegui, L. Nieto-Barrado, C. Perez-Lopez and C. Mayor-Ruiz, *Chem. Soc. Rev.*, 2022, 51, 5498–5517.
- 11 J. A. Dewey, C. Delalande, S. A. Azizi, V. Lu, D. Antonopoulos and G. Babnigg, *J. Med. Chem.*, 2023, 66, 9278–9296.
- 12 S. An and L. Fu, *EBioMedicine*, 2018, 36, 553–562.
- 13 J. C. Fuller, N. J. Burgoyne and R. M. Jackson, *Drug Discovery Today*, 2009, 14, 155–161.
- 14 M. Toure and C. M. Crews, *Angew. Chem., Int. Ed.*, 2016, 55, 1966–1973.
- 15 T. Neklesa, L. B. Snyder, R. R. Willard, N. Vitale, J. Pizzano, D. A. Gordon, M. Bookbinder, J. Macaluso, H. Dong and C. Ferraro, *J. Clin. Oncol.*, 2019, 37, 10.1200.



- 16 J. Flanagan, Y. Qian, S. Gough, M. Andreoli, M. Bookbinder, G. Cadelina, J. Bradley, E. Rousseau, R. Willard and J. Pizzano, *Cancer Res.*, 2019, **79**, P5-04-18.
- 17 M. Békés, D. R. Langley and C. M. Crews, *Nat. Rev. Drug Discovery*, 2022, **21**, 181–200.
- 18 D. A. Stevens, R. Ewesuedo, A. McDonald, S. Agarwal, P. Henrick, R. Perea, A. Gollerkeri and J. Gollob, *J. Clin. Oncol.*, 2022, **40**, TPS3170.
- 19 E. M. Sontag, R. S. Samant and J. Frydman, *Annu. Rev. Biochem.*, 2017, **86**, 97–122.
- 20 A. Hershko, A. Ciechanover and A. Varshavsky, *Nat. Med.*, 2000, **6**, 1073–1081.
- 21 I. Amm, T. Sommer and D. H. Wolf, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2014, **1843**, 182–196.
- 22 S. B. Qian, M. F. Princiotta, J. R. Bennink and J. W. Yewdell, *J. Biol. Chem.*, 2006, **281**, 392–400.
- 23 N. Zheng and N. Shabek, *Annu. Rev. Biochem.*, 2017, **86**, 129–157.
- 24 M. Schapira, M. F. Calabrese, A. N. Bullock and C. M. Crews, *Nat. Rev. Drug Discovery*, 2019, **18**, 949–963.
- 25 A. Bricelj, C. Steinebach, R. Kuchta, M. Gutschow and I. Susic, *Front. Chem.*, 2021, **9**, 707317.
- 26 S. Asano, Y. Fukuda, F. Beck, A. Aufderheide, F. Forster, R. Danev and W. Baumeister, *Science*, 2015, **347**, 439–442.
- 27 C. G. Pack, H. Yukii, A. Toh-e, T. Kudo, H. Tsuchiya, A. Kaiho, E. Sakata, S. Murata, H. Yokosawa, Y. Sako, W. Baumeister, K. Tanaka and Y. Saeki, *Nat. Commun.*, 2014, **5**, 3396.
- 28 W. H. Choi, Y. Yun, S. Park, J. H. Jeon, J. Lee, J. H. Lee, S. A. Yang, N. K. Kim, C. H. Jung, Y. T. Kwon, D. Han, S. M. Lim and M. J. Lee, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 19190–19200.
- 29 K. Tanaka and A. Ichihara, *Biochem. Biophys. Res. Commun.*, 1989, **159**, 1309–1315.
- 30 D. Finley, *Annu. Rev. Biochem.*, 2009, **78**, 477–513.
- 31 K. Martinez-Fonts, C. Davis, T. Tomita, S. Elsasser, A. R. Nager, Y. Shi, D. Finley and A. Matouschek, *Nat. Commun.*, 2020, **11**, 477.
- 32 J. Rabl, D. M. Smith, Y. Yu, S. C. Chang, A. L. Goldberg and Y. Cheng, *Mol. Cell*, 2008, **30**, 360–368.
- 33 E. Seemuller, A. Lupas, D. Stock, J. Lowe, R. Huber and W. Baumeister, *Science*, 1995, **268**, 579–582.
- 34 B. Fabre, T. Lambour, J. Delobel, F. Amalric, B. Monsarrat, O. Burlet-Schiltz and M. P. Bousquet-Dubouch, *Mol. Cell. Proteomics*, 2013, **12**, 687–699.
- 35 B. Fabre, T. Lambour, L. Garrigues, M. Ducoux-Petit, F. Amalric, B. Monsarrat, O. Burlet-Schiltz and M. P. Bousquet-Dubouch, *J. Proteome Res.*, 2014, **13**, 3027–3037.
- 36 C. Zhao and F. J. Dekker, *ACS Pharmacol. Transl. Sci.*, 2022, **5**, 710–723.
- 37 M. Uhlen, L. Fagerberg, B. M. Hallstrom, C. Lindskog, P. Oksvold, A. Mardinoglu, A. Sivertsson, C. Kampf, E. Sjostedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C. A. Szigartyo, J. Odeberg, D. Djureinovic, J. O. Takanen, S. Hober, T. Alm, P. H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J. M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen and F. Ponten, *Science*, 2015, **347**, 1260419.
- 38 Y. Makarov, A. Raiff, R. T. Timms, A. R. Wagh, M. I. Gueta, A. Bekturova, J. Guez-Haddad, S. Brodsky, Y. Opatowsky, M. H. Glickman, S. J. Elledge and I. Koren, *Mol. Cell*, 2023, **83**, 1921–1935.
- 39 D. C. Rubinsztein, P. Codogno and B. Levine, *Nat. Rev. Drug Discovery*, 2012, **11**, 709–730.
- 40 G. E. Mortimore and C. M. Schworer, *Nature*, 1977, **270**, 174–176.
- 41 G. Filomeni, D. De Zio and F. Cecconi, *Cell Death Differ.*, 2015, **22**, 377–388.
- 42 J. Huang and J. H. Brumell, *Nat. Rev. Microbiol.*, 2014, **12**, 101–114.
- 43 A. Stolz, A. Ernst and I. Dikic, *Nat. Cell Biol.*, 2014, **16**, 495–501.
- 44 H. Weidberg, E. Shvets and Z. Elazar, *Annu. Rev. Biochem.*, 2011, **80**, 125–156.
- 45 Y. K. Lee and J. A. Lee, *BMB Rep.*, 2016, **49**, 424–430.
- 46 V. I. Korolchuk, A. Mansilla, F. M. Menzies and D. C. Rubinsztein, *Mol. Cell*, 2009, **33**, 517–527.
- 47 J. H. Lee, S. Park, E. Kim and M. J. Lee, *Autophagy*, 2019, **15**, 726–728.
- 48 E. Adriaenssens, L. Ferrari and S. Martens, *Curr. Biol.*, 2022, **32**, R1357–R1371.
- 49 Z. Li, C. Wang, Z. Wang, C. Zhu, J. Li, T. Sha, L. Ma, C. Gao, Y. Yang, Y. Sun, J. Wang, X. Sun, C. Lu, M. Difiglia, Y. Mei, C. Ding, S. Luo, Y. Dang, Y. Ding, Y. Fei and B. Lu, *Nature*, 2019, **575**, 203–209.
- 50 S. M. Banik, K. Pedram, S. Wisnovsky, G. Ahn, N. M. Riley and C. R. Bertozzi, *Nature*, 2020, **584**, 291–297.
- 51 C. H. Ji, H. Y. Kim, M. J. Lee, A. J. Heo, D. Y. Park, S. Lim, S. Shin, S. Ganipiseti, W. S. Yang, C. A. Jung, K. Y. Kim, E. H. Jeong, S. H. Park, S. Bin Kim, S. J. Lee, J. E. Na, J. I. Kang, H. M. Chi, H. T. Kim, Y. K. Kim, B. Y. Kim and Y. T. Kwon, *Nat. Commun.*, 2022, **13**, 904.
- 52 K. Pance, J. A. Gramespacher, J. R. Byrnes, F. Salangsang, J. C. Serrano, A. D. Cotton, V. Steri and J. A. Wells, *Nat. Biotechnol.*, 2023, **41**, 273–281.
- 53 J. Zheng, W. He, J. Li, X. Feng, Y. Li, B. Cheng, Y. Zhou, M. Li, K. Liu, X. Shao, J. Zhang, H. Li, L. Chen and L. Fang, *J. Am. Chem. Soc.*, 2022, **144**, 21831–21836.
- 54 C. Zhu, W. Wang, Y. Wang, Y. Zhang and J. Li, *Angew. Chem., Int. Ed.*, 2023, **62**, e202300694.
- 55 C. Bashore, S. Prakash, M. C. Johnson, R. J. Conrad, I. A. Kekessie, S. J. Scales, N. Ishisoko, T. Kleinheinz, P. S. Liu, N. Popovych, A. T. Weckler, L. Zhou, C. Tam, I. Zilberleyb, R. Srinivasan, R. A. Blake, A. Song, S. T. Staben, Y. Zhang, D. Arnott, W. J. Fairbrother, S. A. Foster, I. E. Wertz, C. Ciferri and E. C. Dueber, *Nat. Chem. Biol.*, 2023, **19**, 55–63.
- 56 M. Balzarini, W. Gui, I. M. Jayalath, B.-B. Schell, J. Tong and T. Kodadek, *bioRxiv*, 2023, preprint, DOI: [10.1101/2023.07.19.549534](https://doi.org/10.1101/2023.07.19.549534).



- 57 E. J. Bennett, T. A. Shaler, B. Woodman, K. Y. Ryu, T. S. Zaitseva, C. H. Becker, G. P. Bates, H. Schulman and R. R. Kopito, *Nature*, 2007, **448**, 704–708.
- 58 U. B. Pandey, Z. Nie, Y. Batlevi, B. A. McCray, G. P. Ritson, N. B. Nedelsky, S. L. Schwartz, N. A. DiProspero, M. A. Knight, O. Schuldiner, R. Padmanabhan, M. Hild, D. L. Berry, D. Garza, C. C. Hubbert, T. P. Yao, E. H. Baehrecke and J. P. Taylor, *Nature*, 2007, **447**, 859–863.
- 59 S. Sarkar and D. C. Rubinsztein, *FEBS J.*, 2008, **275**, 4263–4270.
- 60 E. Kim, S. Park, J. H. Lee, J. Y. Mun, W. H. Choi, Y. Yun, J. Lee, J. H. Kim, M. J. Kang and M. J. Lee, *Cell Rep.*, 2018, **24**, 732–743.
- 61 S. Fishbain, T. Inobe, E. Israeli, S. Chavali, H. Yu, G. Kago, M. M. Babu and A. Matouschek, *Nat. Struct. Mol. Biol.*, 2015, **22**, 214–221.
- 62 M. A. Kalchman, R. K. Graham, G. Xia, H. B. Koide, J. G. Hodgson, K. C. Graham, Y. P. Goldberg, R. D. Gietz, C. M. Pickart and M. R. Hayden, *J. Biol. Chem.*, 1996, **271**, 19385–19394.
- 63 P. Venkatraman, R. Wetzels, M. Tanaka, N. Nukina and A. L. Goldberg, *Mol. Cell*, 2004, **14**, 95–104.
- 64 F. Gasset-Rosa, C. Chillon-Marin, A. Goginashvili, R. S. Atwal, J. W. Artates, R. Tabet, V. C. Wheeler, A. G. Bang, D. W. Cleveland and C. Lagier-Tourenne, *Neuron*, 2017, **94**, 48–57.
- 65 H. Li, S. H. Li, Z. X. Yu, P. Shelbourne and X. J. Li, *J. Neurosci.*, 2001, **21**, 8473–8481.
- 66 D. Takahashi, J. Moriyama, T. Nakamura, E. Miki, E. Takahashi, A. Sato, T. Akaike, K. Itto-Nakama and H. Arimoto, *Mol. Cell*, 2019, **76**, 797–810.
- 67 Y. Fu, N. Chen, Z. Wang, S. Luo, Y. Ding and B. Lu, *Cell Res.*, 2021, **31**, 965–979.
- 68 Y. Zhang, J. Huang, Y. Liang, J. Huang, Y. Fu, N. Chen, B. Lu and C. Zhao, *Autophagy*, 2023, **19**, 2668–2681.
- 69 M. Liu, Z. Liu, G. Qin, J. Ren and X. Qu, *Nano Lett.*, 2023, **23**, 4965–4973.
- 70 Z. Liu, G. Qin, J. Yang, W. Wang, W. Zhang, B. Lu, J. Ren and X. Qu, *Chem. Sci.*, 2023, **14**, 11192–11202.
- 71 M. Blind and M. Blank, *Mol. Ther.–Nucleic Acids*, 2015, **4**, e223.
- 72 J. Pei, X. Pan, A. Wang, W. Shuai, F. Bu, P. Tang, S. Zhang, Y. Zhang, G. Wang and L. Ouyang, *Chem. Commun.*, 2021, **57**, 13194–13197.
- 73 G. Dong, Y. Wu, J. Cheng, L. Chen, R. Liu, Y. Ding, S. Wu, J. Ma and C. Sheng, *J. Med. Chem.*, 2022, **65**, 7619–7628.
- 74 Y. Zeng, J. Xiao, Y. Xu, F. Wei, L. Tian, Y. Gao, Y. Chen and Y. Hu, *J. Med. Chem.*, 2023, **66**, 12877–12893.
- 75 C. M. Olson, B. Jiang, M. A. Erb, Y. Liang, Z. M. Doctor, Z. Zhang, T. Zhang, N. Kwiatkowski, M. Boukhali, J. L. Green, W. Haas, T. Nomanbhoy, E. S. Fischer, R. A. Young, J. E. Bradner, G. E. Winter and N. S. Gray, *Nat. Chem. Biol.*, 2018, **14**, 163–170.
- 76 A. Folger and Y. Wang, *Cells*, 2021, **10**, 2835.
- 77 H. Olzscha, *Biol. Chem.*, 2019, **400**, 895–915.
- 78 C. Alquezar, S. Arya and A. W. Kao, *Front. Neurol.*, 2021, **11**, 595532.
- 79 D. A. T. Nijholt, L. De Kimpe, H. L. Elfrink, J. J. M. Hoozemans and W. Scheper, *Curr. Med. Chem.*, 2011, **18**, 2459–2476.
- 80 A. Ciechanover and Y. T. Kwon, *Exp. Mol. Med.*, 2015, **47**, e147.
- 81 C. H. Ji, M. J. Lee, H. Y. Kim, A. J. Heo, D. Y. Park, Y. K. Kim, B. Y. Kim and Y. T. Kwon, *Autophagy*, 2022, **18**, 2259–2262.
- 82 J. Lee, K. W. Sung, E. J. Bae, D. Yoon, D. Kim, J. S. Lee, D. H. Park, D. Y. Park, S. R. Mun, S. C. Kwon, H. Y. Kim, J. O. Min, S. J. Lee, Y. H. Suh and Y. T. Kwon, *Mol. Neurodegener.*, 2023, **18**, 41.
- 83 A. Varshavsky, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 358–366.
- 84 Y. Jiang, J. Lee, J. H. Lee, J. W. Lee, J. H. Kim, W. H. Choi, Y. D. Yoo, H. Cha-Molstad, B. Y. Kim, Y. T. Kwon, S. A. Noh, K. P. Kim and M. J. Lee, *Autophagy*, 2016, **12**, 2197–2212.
- 85 M. J. Lee, D. E. Kim, A. Zakrzewska, Y. D. Yoo, S. H. Kim, S. T. Kim, J. W. Seo, Y. S. Lee, G. W. Dorn, 2nd, U. Oh, B. Y. Kim and Y. T. Kwon, *J. Biol. Chem.*, 2012, **287**, 24043–24052.
- 86 H. Cha-Molstad, K. S. Sung, J. Hwang, K. A. Kim, J. E. Yu, Y. D. Yoo, J. M. Jang, D. H. Han, M. Molstad, J. G. Kim, Y. J. Lee, A. Zakrzewska, S. H. Kim, S. T. Kim, S. Y. Kim, H. G. Lee, N. K. Soung, J. S. Ahn, A. Ciechanover, B. Y. Kim and Y. T. Kwon, *Nat. Cell Biol.*, 2015, **17**, 917–929.
- 87 H. Cha-Molstad, J. E. Yu, Z. Feng, S. H. Lee, J. G. Kim, P. Yang, B. Han, K. W. Sung, Y. D. Yoo, J. Hwang, T. McGuire, S. M. Shim, H. D. Song, S. Ganipiseti, N. Wang, J. M. Jang, M. J. Lee, S. J. Kim, K. H. Lee, J. T. Hong, A. Ciechanover, I. Mook-Jung, K. P. Kim, X. Q. Xie, Y. T. Kwon and B. Y. Kim, *Nat. Commun.*, 2017, **8**, 102.
- 88 A. J. Jakobi, S. T. Huber, S. A. Mortensen, S. W. Schultz, A. Palara, T. Kuhm, B. K. Shrestha, T. Lamark, W. J. H. Hagen, M. Wilmanns, T. Johansen, A. Brech and C. Sachse, *Nat. Commun.*, 2020, **11**, 440.
- 89 C. H. Ji, H. Y. Kim, A. J. Heo, S. H. Lee, M. J. Lee, S. B. Kim, G. Srinivasrao, S. R. Mun, H. Cha-Molstad, A. Ciechanover, C. Y. Choi, H. G. Lee, B. Y. Kim and Y. T. Kwon, *Mol. Cell*, 2019, **75**, 1058–1072.
- 90 Y. J. Lee, J. K. Kim, C. H. Jung, Y. J. Kim, E. J. Jung, S. H. Lee, H. R. Choi, Y. S. Son, S. M. Shim, S. M. Jeon, J. H. Choe, S. H. Lee, J. Whang, K. C. Sohn, G. M. Hur, H. T. Kim, J. Yeom, E. K. Jo and Y. T. Kwon, *Autophagy*, 2022, **18**, 2926–2945.
- 91 S. M. Shim, H. R. Choi, S. C. Kwon, H. Y. Kim, K. W. Sung, E. J. Jung, S. R. Mun, T. H. Bae, D. H. Kim, Y. S. Son, C. H. Jung, J. Lee, M. J. Lee, J. W. Park and Y. T. Kwon, *Autophagy*, 2023, **19**, 1642–1661.
- 92 L. Xiao, M. Xiao, M. Zou and W. Xu, *Int. J. Clin. Exp. Pathol.*, 2017, **10**, 8569–8576.
- 93 J. M. Molina-Molina, A. Hillenweck, I. Jouanin, D. Zalko, J. P. Cravedi, M. F. Fernández, A. Pillon, J. C. Nicolas, N. Olea and P. Balaguer, *Toxicol. Appl. Pharmacol.*, 2006, **216**, 44–54.
- 94 E. C. Griffith, Z. Su, S. Niwayama, C. A. Ramsay, Y. H. Chang and J. O. Liu, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 15183–15188.



- 95 L. Cortez and V. Sim, *Prion*, 2014, **8**, 197–202.
- 96 L. Antonschmidt, D. Matthes, R. Dervişoğlu, B. Frieg, C. Dienemann, A. Leonov, E. Nimerovsky, V. Sant, S. Ryazanov, A. Giese, G. F. Schröder, S. Becker, B. L. de Groot, C. Griesinger and L. B. Andreas, *Nat. Commun.*, 2022, **13**, 5385.
- 97 D. Matthes, V. Gapsys, C. Griesinger and B. L. de Groot, *ACS Chem. Neurosci.*, 2017, **8**, 2791–2808.
- 98 J. Lewis, E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. Van Slegtenhorst, K. Gwinn-Hardy, M. Paul Murphy, M. Baker, X. Yu, K. Duff, J. Hardy, A. Corral, W. L. Lin, S. H. Yen, D. W. Dickson, P. Davies and M. Hutton, *Nat. Genet.*, 2000, **25**, 402–405.
- 99 E. F. Kuiper, E. P. de Mattos, L. B. Jardim, H. H. Kampinga and S. Bergink, *Front. Neurosci.*, 2017, **11**, 145.
- 100 N. Kedia, K. Arhzaouy, S. K. Pittman, Y. Sun, M. Batchelor, C. C. Weihl and J. Bieschke, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 16835–16840.
- 101 S. Shin, D. Kim, J. Y. Song, H. Jeong, S. J. Hyeon, N. W. Kowall, H. Ryu, A. N. Pae, S. Lim and Y. K. Kim, *Prog. Neurobiol.*, 2020, 101782.
- 102 D. H. Han, H. K. Na, W. H. Choi, J. H. Lee, Y. K. Kim, C. Won, S. H. Lee, K. P. Kim, J. Kuret, D. H. Min and M. J. Lee, *Nat. Commun.*, 2014, **5**, 5633.
- 103 V. Sharma, S. Verma, E. Seranova, S. Sarkar and D. Kumar, *Front. Cell Dev. Biol.*, 2018, **6**, 147.
- 104 Y. W. Wu and F. Li, *Virulence*, 2019, **10**, 352–362.
- 105 J. M. Yuk, T. Yoshimori and E. K. Jo, *Exp. Mol. Med.*, 2012, **44**, 99–108.
- 106 E. Campoy and M. I. Colombo, *Curr. Top. Microbiol. Immunol.*, 2009, **335**, 227–250.
- 107 N. N. Noda, Z. Wang and H. Zhang, *J. Cell Biol.*, 2020, **219**, e202004062.
- 108 T. Lamark and T. Johansen, *Annu. Rev. Cell Dev. Biol.*, 2021, **37**, 143–169.
- 109 S. Ghaemmaghani, W. K. Huh, K. Bower, R. W. Howson, A. Belle, N. Dephoure, E. K. O'Shea and J. S. Weissman, *Nature*, 2003, **425**, 737–741.
- 110 P. Ghosh, N. M. Dahms and S. Kornfeld, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 202–212.
- 111 E. Dalle Vedove, G. Costabile and O. M. Merkel, *Adv. Healthcare Mater.*, 2018, **7**, e1701398.
- 112 D. B. Oh, *BMB Rep.*, 2015, **48**, 438–444.
- 113 L. Beljaars, G. Molema, B. Weert, H. Bonnema, P. Olinga, G. M. Groothuis, D. K. Meijer and K. Poelstra, *Hepatology*, 1999, **29**, 1486–1493.
- 114 D. B. Berkowitz, G. Maiti, B. D. Charette, C. D. Dreis and R. G. MacDonald, *Org. Lett.*, 2004, **6**, 4921–4924.
- 115 G. Ahn, N. M. Riley, R. A. Kamber, S. Wisnovsky, S. Moncayo von Hase, M. C. Bassik, S. M. Banik and C. R. Bertozzi, *Science*, 2023, **382**, eadf6249.
- 116 M. Safieh, A. D. Korczyn and D. M. Michaelson, *BMC Med.*, 2019, **17**, 64.
- 117 M. L. Burr, C. E. Sparbier, Y. C. Chan, J. C. Williamson, K. Woods, P. A. Beavis, E. Y. N. Lam, M. A. Henderson, C. C. Bell, S. Stolzenburg, O. Gilan, S. Bloor, T. Noori, D. W. Morgens, M. C. Bassik, P. J. Neeson, A. Behren, P. K. Darcy, S. J. Dawson, I. Voskoboinik, J. A. Trapani, J. Cebon, P. J. Lehner and M. A. Dawson, *Nature*, 2017, **549**, 101–105.
- 118 P. Huang, X. Xu, L. Wang, B. Zhu, X. Wang and J. Xia, *J. Cell. Mol. Med.*, 2014, **18**, 218–230.
- 119 X. Zhang, H. Liu, J. He, C. Ou, T. C. Donahue, M. M. Muthana, L. Su and L. X. Wang, *ACS Chem. Biol.*, 2022, **17**, 3013–3023.
- 120 T. S. Zimmermann, V. Karsten, A. Chan, J. Chiesa, M. Boyce, B. R. Bettencourt, R. Hutabarat, S. Nochur, A. Vaishnav and J. Gollob, *Mol. Ther.*, 2017, **25**, 71–78.
- 121 R. J. Stockert, *Physiol. Rev.*, 1995, **75**, 591–609.
- 122 M. Spiess, *Biochemistry*, 1990, **29**, 10009–10018.
- 123 M. Egli and M. Manoharan, *Nucleic Acids Res.*, 2023, **51**, 2529–2573.
- 124 G. Ahn, S. M. Banik, C. L. Miller, N. M. Riley, J. R. Cochran and C. R. Bertozzi, *Nat. Chem. Biol.*, 2021, **17**, 937–946.
- 125 D. Rabuka, J. S. Rush, G. W. de Hart, P. Wu and C. R. Bertozzi, *Nat. Protoc.*, 2012, **7**, 1052–1067.
- 126 D. F. Caianiello, M. Zhang, J. D. Ray, R. A. Howell, J. C. Swartzel, E. M. J. Branham, E. Chirkin, V. R. Sabbasani, A. Z. Gong, D. M. McDonald, V. Muthusamy and D. A. Spiegel, *Nat. Chem. Biol.*, 2021, **17**, 947–953.
- 127 Y. Zhou, P. Teng, N. T. Montgomery, X. Li and W. Tang, *ACS Cent. Sci.*, 2021, **7**, 499–506.
- 128 G. Kaur and I. Roy, *Expert Opin. Invest. Drugs*, 2008, **17**, 43–60.
- 129 Y. Miao, Q. Gao, M. Mao, C. Zhang, L. Yang, Y. Yang and D. Han, *Angew. Chem., Int. Ed.*, 2021, **60**, 11267–11271.
- 130 K. Hamada, T. Hashimoto, R. Iwashita, Y. Yamada, Y. Kikkawa and M. Nomizu, *Cell Rep. Phys. Sci.*, 2023, **4**, 101296.
- 131 Y. Wu, B. Lin, Y. Lu, L. Li, K. Deng, S. Zhang, H. Zhang, C. Yang and Z. Zhu, *Angew. Chem., Int. Ed.*, 2023, **62**, e202218106.
- 132 A. Lacroix and H. F. Sleiman, *ACS Nano*, 2021, **15**, 3631–3645.
- 133 M. E. Distler, M. H. Teplensky, K. E. Bujold, C. D. Kusmierz, M. Evangelopoulos and C. A. Mirkin, *J. Am. Chem. Soc.*, 2021, **143**, 13513–13518.
- 134 D. Zhang, J. Duque-Jimenez, G. Brix, F. Facchinetti, K. Rhee, W. W. Feng, P. A. Jänne and X. Zhou, *bioRxiv*, 2023, preprint, DOI: [10.1101/2023.08.10.552782](https://doi.org/10.1101/2023.08.10.552782).
- 135 B. Huang, M. Abedi, G. Ahn, B. Coventry, I. Sappington, R. Wang, T. Schlichthaerle, J. Z. Zhang, Y. Wang, I. Goresnik, C. W. Chiu, A. Chazin-Gray, S. Chan, S. Gerben, A. Murray, S. Wang, J. O'Neill, R. Yeh, A. Misquith, A. Wolf, L. M. Tomasovic, D. I. Piraner, M. J. D. Gonzalez, N. R. Bennett, P. Venkatesh, D. Satoe, M. Ahlrichs, C. Dobbins, W. Yang, X. Wang, D. Vafeados, R. Mout, S. Shivaie, L. Cao, L. Carter, L. Stewart, J. B. Spangler, G. J. L. Bernardes, K. T. Roybal, J. Per Greisen, X. Li, C. Bertozzi and D. Baker, *bioRxiv*, 2023, preprint, DOI: [10.1101/2023.08.19.553321](https://doi.org/10.1101/2023.08.19.553321).
- 136 P. S. Dragovich, T. H. Pillow, R. A. Blake, J. D. Sadowsky, E. Adaligil, P. Adhikari, S. Bhakta, N. Blaquiére, J. Chen,



- J. Dela Cruz-Chuh, K. E. Gascoigne, S. J. Hartman, M. He, S. Kaufman, T. Kleinheinz, K. R. Kozak, L. Liu, L. Liu, Q. Liu, Y. Lu, F. Meng, M. M. Mulvihill, A. O'Donohue, R. K. Rowntree, L. R. Staben, S. T. Staben, J. Wai, J. Wang, B. Wei, C. Wilson, J. Xin, Z. Xu, H. Yao, D. Zhang, H. Zhang, H. Zhou and X. Zhu, *J. Med. Chem.*, 2021, **64**, 2534–2575.
- 137 M. A. Maneiro, N. Forte, M. M. Shchepinova, C. S. Kounde, V. Chudasama, J. R. Baker and E. W. Tate, *ACS Chem. Biol.*, 2020, **15**, 1306–1312.
- 138 H. Zhang, Y. Han, Y. Yang, F. Lin, K. Li, L. Kong, H. Liu, Y. Dang, J. Lin and P. R. Chen, *J. Am. Chem. Soc.*, 2021, **143**, 16377–16382.
- 139 A. D. Cotton, D. P. Nguyen, J. A. Gramespacher, I. B. Seiple and J. A. Wells, *J. Am. Chem. Soc.*, 2021, **143**, 593–598.
- 140 H. Marei, W. K. Tsai, Y. S. Kee, K. Ruiz, J. He, C. Cox, T. Sun, S. Penikalapati, P. Dwivedi, M. Choi, D. Kan, P. Saenz-Lopez, K. Dorigi, P. Zhang, Y. T. Kschonsak, N. Kljavin, D. Amin, I. Kim, A. G. Mancini, T. Nguyen, C. Wang, E. Janezic, A. Doan, E. Mai, H. Xi, C. Gu, M. Heinlein, B. Biehs, J. Wu, I. Lehoux, S. Harris, L. Comps-Agrar, D. Seshasayee, F. J. de Sauvage, M. Grimmer, J. Li, N. J. Agard and E. M. F. de Sousa, *Nature*, 2022, **610**, 182–189.
- 141 J. B. Ridgway, L. G. Presta and P. Carter, *Protein Eng.*, 1996, **9**, 617–621.
- 142 A. H. Boekhout, J. H. Beijnen and J. H. Schellens, *Oncologist*, 2011, **16**, 800–810.
- 143 S. Li, K. R. Schmitz, P. D. Jeffrey, J. J. Wiltzius, P. Kussie and K. M. Ferguson, *Cancer Cell*, 2005, **7**, 301–311.
- 144 S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton and M. Sznol, *N. Engl. J. Med.*, 2012, **366**, 2443–2454.
- 145 C. M. Pickart and R. E. Cohen, *Nat. Rev. Mol. Cell Biol.*, 2004, **5**, 177–187.
- 146 A. W. Karzai, E. D. Roche and R. T. Sauer, *Nat. Struct. Biol.*, 2000, **7**, 449–455.
- 147 R. T. Sauer and T. A. Baker, *Annu. Rev. Biochem.*, 2011, **80**, 587–612.
- 148 S. Bar-Nun and M. H. Glickman, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2012, **1823**, 67–82.
- 149 R. F. Kalejta and T. Shenk, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 3263–3268.
- 150 B. Donati, E. Lorenzini and A. Ciarrocchi, *Mol. Cancer*, 2018, **17**, 164.
- 151 H. S. Kruth, N. L. Jones, W. Huang, B. Zhao, I. Ishii, J. Chang, C. A. Combs, D. Malide and W. Y. Zhang, *J. Biol. Chem.*, 2005, **280**, 2352–2360.
- 152 S. D. Conner and S. L. Schmid, *Nature*, 2003, **422**, 37–44.
- 153 N. Liu, R. Ling, X. Tang, Y. Yu, Y. Zhou and D. Chen, *Front. Oncol.*, 2022, **12**, 847701.
- 154 E. M. H. Ali, C. A. Loy and D. J. Trader, *bioRxiv*, 2024, preprint, DOI: [10.1101/2024.01.20.576376](https://doi.org/10.1101/2024.01.20.576376).
- 155 A. Mullard, *Nat. Rev. Drug Discovery*, 2019, **18**, 237–239.
- 156 L. Zhang, B. Riley-Gillis, P. Vijay and Y. Shen, *Mol. Cancer Ther.*, 2019, **18**, 1302–1311.
- 157 K. Yang, Y. Zhao, X. Nie, H. Wu, B. Wang, C. M. Almodovar-Rivera, H. Xie and W. Tang, *Cell Chem. Biol.*, 2020, **27**, 866–876.
- 158 C. Otto, S. Schmidt, C. Kastner, S. Denk, J. Kettler, N. Muller, C. T. Germer, E. Wolf, P. Gallant and A. Wiegering, *Neoplasia*, 2019, **21**, 1110–1120.
- 159 A. R. Wyatt, J. J. Yerbury, S. Poon and M. R. Wilson, *Curr. Med. Chem.*, 2009, **16**, 2855–2866.
- 160 W. J. Liu, L. Ye, W. F. Huang, L. J. Guo, Z. G. Xu, H. L. Wu, C. Yang and H. F. Liu, *Cell. Mol. Biol. Lett.*, 2016, **21**, 29.
- 161 W. K. Wu, C. H. Cho, C. W. Lee, Y. C. Wu, L. Yu, Z. J. Li, C. C. Wong, H. T. Li, L. Zhang, S. X. Ren, C. T. Che, K. Wu, D. Fan, J. Yu and J. J. Sung, *Autophagy*, 2010, **6**, 228–238.
- 162 K. Zhu, K. Dunner, Jr. and D. J. McConkey, *Oncogene*, 2010, **29**, 451–462.
- 163 S. Kageyama, Y. S. Sou, T. Uemura, S. Kametaka, T. Saito, R. Ishimura, T. Kouno, L. Bedford, R. J. Mayer, M. S. Lee, M. Yamamoto, S. Waguri, K. Tanaka and M. Komatsu, *J. Biol. Chem.*, 2014, **289**, 24944–24955.
- 164 N. Forte, D. Dovala, M. J. Hesse, J. M. McKenna, J. A. Tallarico, M. Schirle and D. K. Nomura, *ACS Chem. Biol.*, 2023, **18**, 897–904.
- 165 M. Meyers, S. Cismoski, A. Panidapu, B. Chie-Leon and D. K. Nomura, *bioRxiv*, 2023, preprint, DOI: [10.1101/2023.08.11.553046](https://doi.org/10.1101/2023.08.11.553046).
- 166 E. V. Rusilowicz-Jones, S. Urbe and M. J. Clague, *Mol. Cell*, 2022, **82**, 1414–1423.
- 167 J. Zhao, B. Zhai, S. P. Gygi and A. L. Goldberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 15790–15797.
- 168 S. B. Cambridge, F. Gnad, C. Nguyen, J. L. Bermejo, M. Kruger and M. Mannw, *J. Proteome Res.*, 2011, **10**, 5275–5284.
- 169 Y. Dong, S. Zhang, Z. Wu, X. Li, W. L. Wang, Y. Zhu, S. Stoilova-McPhie, Y. Lu, D. Finley and Y. Mao, *Nature*, 2019, **565**, 49–55.

